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1. Abbreviations  
AD, Alzheimer’s disease  
CAA, cerebral amyloid angiopathy 
CDR, clinical dementia rating scale  
CSF, cerebrospinal fluid 
DLB, Dementia with Lewy-bodies   
LBD, Lewy-body dementia (DLB and PDD) 
MMSE, Mini Mental Status Examination  
MRI, magnetic resonance imaging  
NPI, Neuropsychiatric Inventory  
NPS, neuropsychiatric symptoms 
PDD, Parkinson’s disease dementia 
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Aim: Neuropsychiatric symptoms (NPS) such as anxiety, apathy, and psychosis are 
important manifestations of dementia that have a major impact on the patient’s 
quality of life, carer burden, and risk of institutionalisation. There are few treatment 
options, the clinical course is not understood, and the mechanism behind the 
symptoms is unknown. This thesis analyses the frequency, long-term course, and 
pathological underpinnings of NPS.  
Methods: The Demvest study is a 12-year prospective longitudinal multicentre 
cohort study in the western part of Norway. Among the 667 patients with suspected 
mild dementia who were screened, 223 fulfilled the inclusion criteria were included 
and followed with annual assessments using the Neuropsychiatric Inventory (NPI). 
The attrition rate was very low, and data from 56 patients who underwent autopsy 
after death confirmed that the clinical diagnoses were highly accurate. The diagnostic 
distribution was 113 patients with Alzheimer’s disease (AD), 86 patients with Lewy-
body dementia (LBD), and 24 patients with other types of dementia. 
Results: NPS were common at baseline and only a moderate increase in NPS was 
observed during the first 5 years. There was also no increase in the proportion of 
patients with high NPI total scores. LBD was associated with a higher NPI total score 
and higher psychotic symptom scores. Most patients had a relapsing course or single 
symptomatic episodes rather than persistent symptoms, and 57% of AD and 84% of 
DLB patients had reoccurring psychotic symptoms. We found a significant 
association between cerebral amyloid angiopathy and psychosis in AD.  
Discussion: Severe NPS are already common at time of dementia diagnosis, and their 
increase with disease progression is moderate. We observed a highly individual 
course of NPS with unstable symptomatology. Cerebrovascular disease may increase 
the risk of psychosis in AD. The individual variations in NPS over time underline the 
need for personalised medicine in dementia care. NPS, including psychotic 
symptoms, should be highlighted as a natural part of the dementia syndrome. 
7 
 
5. List of publications 
Article 1 [1]       
Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study 
International Journal Geriatric Psychiatry, 2018 
 
Article 2 [2] 
The individual course of neuropsychiatric symptoms in people with Alzheimer’s and Lewy 
body dementia: a 12-year longitudinal cohort study 
Submitted 
 
Article 3 [3] 
Advanced cerebral amyloid angiopathy and small vessel disease are associated with 
psychosis in Alzheimer’s disease.   













1. ABBREVIATIONS .................................................................................................................... 3 
2. SCIENTIFIC ENVIRONMENT .............................................................................................. 4 
3. ACKNOWLEDGEMENTS ...................................................................................................... 5 
4. ABSTRACT ............................................................................................................................... 6 
5. LIST OF PUBLICATIONS ...................................................................................................... 7 
6. CONTENTS ............................................................................................................................... 8 
7. INTRODUCTION ................................................................................................................... 10 
7.1 DEMENTIA ............................................................................................................................. 11 
7.2 CAUSES OF DEMENTIA ........................................................................................................... 12 
7.2.1 Alzheimer’s disease .................................................................................................... 13 
7.2.2 Dementia with Lewy-bodies ....................................................................................... 18 
7.2.3 Other dementias ......................................................................................................... 21 
7.3 NEUROPSYCHIATRIC SYMPTOMS ........................................................................................... 24 
7.3.2 Frequency of neuropsychiatric symptoms .................................................................. 27 
7.3.3 Persistency of neuropsychiatric symptoms ................................................................. 29 
7.3.4 Individual patient’s course ......................................................................................... 30 
7.3.5 NPS according to dementia type ................................................................................ 31 
7.3.6 Pathogenesis .............................................................................................................. 32 
7.3.7 Management ............................................................................................................... 33 
7.4 PSYCHOTIC SYMPTOMS .......................................................................................................... 35 
7.4.2 Frequency ................................................................................................................... 36 
7.4.3 Course ........................................................................................................................ 36 
9 
 
7.4.4 Pathological mechanisms ........................................................................................... 37 
7.4.5 Cerebral amyloid angiopathy ..................................................................................... 38 
8. AIMS ......................................................................................................................................... 40 
9. METHODOLOGICAL CONSIDERATIONS ....................................................................... 41 
9.1 VALIDITY OF THE DEMVEST STUDY ....................................................................................... 41 
9.2 MEASUREMENT OF NPS ......................................................................................................... 49 
9.3 NEUROPATHOLOGY ................................................................................................................ 53 
9.4 ETHICS AND LEGALITY ........................................................................................................... 56 
10. RESULTS .................................................................................................................................. 58 
11. DISCUSSION ............................................................................................................................ 60 
11.1 FINDINGS IN CONTEXT....................................................................................................... 61 
11.2 LONGITUDINAL COURSE OF NPS ....................................................................................... 71 
11.3 DIFFERENCES BETWEEN AD AND DLB ............................................................................. 75 
11.4 NEUROPATHOLOGICAL CORRELATES OF NPS ................................................................... 78 
12. CONCLUSIONS ....................................................................................................................... 80 
13. FUTURE PERSPECTIVE ....................................................................................................... 81 
14. REFERENCES ......................................................................................................................... 82 
15. APPENDEX .............................................................................................................................. 91 
15.2 ARTICLE I ............................................................................................................................. 
15.3 ARTICLE II ............................................................................................................................ 





Dementia is a leading health burden worldwide. It is estimated that one-third of 
elderly people will develop dementia, and up to half of all people aged 85 or older 
will have some form of dementia. The number of people with dementia in Norway is 
expected to increase from 77,000 in 2017 to more than 140,000 in 2040, and this 
represents a great challenge [4]. Most other countries have lower societal resources 
and higher increases in life expectancy. There are neither economic resources nor 
health carers to accommodate the future increase in dementia patients’ needs using 
the current practice. The World Health Organisation (WHO) raised dementia care as 
a global challenge and included it in the United Nations goals for sustainable 
development because the search for better and more precise treatment is imminent 
[5].  
During the last decade, the awareness of non-cognitive dementia symptoms has 
increased. The reason for this is probably multifaceted, including stronger individual 
focus, awareness of the costs and burden associated with neuropsychiatric symptoms 
(NPS), and more research in nursing home settings. Additionally, there have been 
important discoveries about the high risk of stroke and death combined with a 
minimal effect of commonly used antipsychotic drugs.  
The frequency and clinical course of NPS are of great importance for clinical 
management and scientific studies. Few studies have explicitly investigated NPS in 
different dementia disorders from a long-term longitudinal perspective. Psychotic 
symptoms are of special interest because of their burden, associated stigma, and 
association with a more severe subgroup. 
This introduction is focused on the NPS frequency and course in two of the most 
common dementia diseases: Alzheimer’s disease (AD) and dementia with Lewy 
bodies (DLB). The psychotic symptoms and their suggested pathogenesis are 




Originally deduced from Latin meaning mad or out of one’s mind, —and for many 
years it was coined with the prefix senile meaning old—it has been a descriptor for a 
wide range of diseases affecting mental function in the elderly.  Unfortunately, the 
term ‘dementia’ often carries unintended cruel lay language connotations and it is 
also medically imprecise, and for this it has been criticised [6]. The revised American 
Psychiatric Association’s DSM-5 has moved away from a diagnosis using the word 
dementia. They, instead, introduced the term ‘neurocognitive disorder’ in an attempt 
to help reduce the stigma and presume that a neurocognitive disorder improves focus 
on the decline rather than on the deficiencies [7].  
Dementia is a syndrome that does not have a specific cause, and it is diagnosed 
according to the criteria of the International Classification of Diseases, version 10 
(ICD-10), which was published by the World Health Organisation (WHO) in 1993 
[8]. This work is based on ICD-10 (see below) and DSM-IV definitions. Because the 
term ‘dementia’ is still in widespread use in clinical practice and research, this term 
will be used throughout the thesis, although I am aware of the variety of different 
definitions.  
ICD-10 Dementia:  
Dementia (F00-F03) is a syndrome due to disease of the brain, usually of a 
chronic or progressive nature, in which there is disturbance of multiple higher 
cortical functions, including memory, thinking, orientation, comprehension, 
calculation, learning capacity, language, and judgement. Consciousness is not 
clouded. The impairments of cognitive function are commonly accompanied, and 
occasionally preceded, by deterioration in emotional control, social behaviour, or 
motivation. This syndrome occurs in Alzheimer’s disease, in cerebrovascular 
disease, and in other conditions primarily or secondarily affecting the brain.  
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7.2 Causes of dementia 
In the scientific literature, all-cause dementia includes several different diseases, but 
with a majority of AD, and varying numbers of patients with Lewy-body dementia 
(LBD), vascular dementia, and frontotemporal lobe dementia (FTLD; Figure 1). 
Ninety-five percent of dementia is caused by those four diseases [9-11]. Depending 
on the cohort recruitment procedures, age, and cardiovascular risk profile, either 
vascular dementia or DLB is the second most common dementia type, and Figure 1 
illustrates the difference in sample recruiting and age. AD and DLB are the focus of 
this thesis and will be described in detail below.  
 
Figure 1. The load of neuropathology in all-cause Mild Cognitive Inhibition (MCI, 
n=150) and not clinically diagnosed as Alzheimer’s disease (NON-AD, n=59) in a 




7.2.1 Alzheimer’s disease 
Epidemiology  
AD is the most common single cause of dementia, accounting for 50%–75% of all 
dementia cases [11]. AD was first formally described by Alois Alzheimer in 1906. 
The incidence is strongly affected by age, roughly doubling in prevalence every 5 
years after age 65. One in 20 Europeans aged ≥65 have Alzheimer’s dementia, and 
this number is expected to double in Western Europe and triple in Eastern Europe by 
2040 [10].   
Pathology 
The most striking diagnostic features of AD pathology is the visible loss of cortical 
brain tissue and inflated ventricles inside the brain. The two major microscopic 
hallmarks are amyloid plaques and neurofibrillary tangles, which are assessed post-
mortem according to staging.   
The first hallmark, neurofibrillary tangles, are aggregates of hyperphosphorylated tau 
protein, which is a naturally occurring protein that is important in microtubules inside 
the cell. Their presence is also found in numerous other diseases, which are known as 
tauopathies and include several types of frontotemporal dementia. Little is known 
about their exact relationship with the different pathologies. The degree and 
localisation of neurofibrillary tangles are described according to the Braak stages. 
Braak stages I and II are used when neurofibrillary tangle involvement is confined 
mainly in the transentorhinal region of the brain, stages III and IV are used with 
involvement of the limbic regions such as the hippocampus, and stages V and VI are 
used when there is extensive neocortical involvement [13]. This should not be 
confused with the degree of senile plaque involvement, which progresses differently. 
Amyloid plaques, or senile plaques, are the second hallmark of AD. The plaques are 
protein aggregates of many different proteins including the amyloid precursor 
protein, which is suggested to have a ‘seed effect’ on development [14]. There are 
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many different species of amyloid with different propensities to aggregate into 
oligomeric and fibrillary forms. The different species also have differentiated effect 
synaptotoxic effects when evaluated in vitro, in situ, and in vivo using experimental 
models of learning and behaviour. Modifying clearance of synaptotoxic elements, 
including amyloid species, from the brain is a promising drug development track 
[15]. The natural function of amyloid is unknown, but it is preserved in evolution and 
produces similar plaques in animals. There are three kinds of amyloid aggregations: 
diffuse plaques, neuritic plaques, and deposited amyloid fibrils in the vessel walls. 
The latter is called cerebral amyloid angiopathy is presented later in the Introduction 
[16].  
The topographical development of amyloid plaques is less ordered and several 
different scoring systems are used. The National Institute of Health and Alzheimer’s 
Association (NIHAA) diagnostic guidelines support categorisation (Thal phase 0–5) 
based on progressive amyloid deposition [17, 18]. The Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) developed an amyloid plaque (neuritic 
and diffuse) scoring system, which ranks the density and type of amyloid plaques in 
the hippocampus and amygdala as well as in the frontal, temporal, parietal, and 
occipital neocortex. The CERAD amyloid pathology score is reported as 0-A-B-C, 
with 0 meaning no pathology and C meaning severe pathology [19]. The different 
scales are highly correlated, but they also describe important differences [14, 17, 19].  
Pathogenesis 
The causes of AD are complex and have not been fully identified. The most common 
late-onset AD is driven by a complex interplay between genetic and environmental 
factors, although the risk that is attributable to genetic factors may be as high as 70%. 
The effect is polygenic with over 29 risk loci that have been identified, and 215 
potential causative genes that implicate inflammation, cholesterol metabolism, 
microglial activation, and other factors [20]. The APOE gene, which has three 
variants, ε2, ε3, and ε4, is the single greatest risk factor for sporadic AD. The clinical 
value of analysing for these variants in individual patients is modest, with an odds 
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ratio (OR) for AD of 3 and 12 in ε4 heterozygotes and homozygotes, respectively. 
Genetic testing for APOE ε4 is not recommended outside of a research setting. 
However, when assessing the effects in cohorts, APOE is an important factor for 
determining disease progression [21].  
There are also rare types of familial AD that are caused by mutations in the amyloid 
precursor protein, presenilin 1, or presenilin 2 genes. People who inherit any of these 
mutations will usually develop Alzheimer’s dementia before 65 years of age. Genetic 
testing and guidance are available for these families [22]. 
Vascular risk factors, loss of hearing, social isolation, and depression are important 
modifiable risk factors. There are many studies with single risk factors that show 
strong associations, such as repeated traumatic head injures (e.g. athletic boxers and 
repeated concussions), sleep disorders, or high levels of air-pollutants from roads. 
The degree to which they influence the risk of AD on a population level or may be 
relevant for a smaller part of the total number is unknown [22, 23]. 
Clinical features 
A gradual onset of cognitive decline in elderly individuals often begins with typical 
features such as short-term memory loss, word-finding difficulties, or personality 
changes. More complex tasks such as orientation outside the familiar milieu, episodic 
memory, and executive function are often affected. As the condition progress, the 
degree of dependence on others also increases dramatically. Insight into ones’ 
symptoms is often occluded or associated with shame, leaving patients in need of 
being referred to medical help by others.  
The clinical diagnosis of Alzheimer’s disease is based on clinical history, physical 
examination, and cognitive screening tests such as the Montreal Cognitive 
Assessment (MOCA) or Mini Mental Status Examination (MMSE), which are 
complimented by more advanced neuropsychological tests as required. There are also 
more structured interviews with carers regarding activities of daily life. A 
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comprehensive assessment to rule out other somatic or psychiatric causes is 
imperative [17]. 
Biomarkers 
Biomarkers are increasingly being used in clinical and research diagnostics. 
Suggested research criteria categorised patients as either normal or abnormal based 
on amyloidosis (A+/−) and neurodegeneration (N+/−) biomarkers [22]. Biomarkers 
of amyloidosis are amyloid positron emission tomography (PET) and cerebrospinal 
fluid (CSF) Aβ42, and established biomarkers of neurodegeneration are CSF tau, 
FDG-PET, and structural MRI. Structural MRI with an assessment of cortical 
thickness and hippocampal atrophy are most frequently used and are included under 
caution in the national guidelines for dementia care [4, 24]. The CSF biomarkers 
Aβ42 (amyloid) and tau (including p-tau and total tau) are used in most large 
diagnostic centres in Norway, as well as in the current study. Internationally, CSF 
biomarkers are gradually becoming more recognised in the research guidelines for 
their diagnostic utility and are being considered for qualification for subject selection 
in clinical trials.  
Definitive and clinical diagnosis 
The definitive diagnosis of AD is made via pathological examination of brain tissue, 
which it is ranked using the three parameters Amyloid, Braak, and CERAD, to obtain 
an ‘ABC score.’ Because of the high incidence of Alzheimer’s pathology in healthy 
elderly people, the clinical data is important. The pathological diagnosis suggested by 
National Institute of Health – Alzheimer’s Association (NIA-AA) is that in 
individuals with cognitive impairment at the time tissue was obtained, only 
intermediate or high levels of AD neuropathological changes should be considered as 
an adequate explanation. When low levels of AD neuropathologic changes are 
observed in the setting of cognitive impairment, it is likely that other diseases are 
present [17].  
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In all patients with cognitive impairment, it is essential to determine the presence or 
absence of other disease(s) that might have contributed to the clinical deficits. For 
patients with incomplete clinical history, large clinicopathologic studies indicate that 
higher levels of AD neuropathologic changes are typically correlated with a greater 
likelihood of cognitive impairment.  
Patients diagnosed with AD without post-mortem assessments are implicitly cases 
with high, intermediate, or low likelihood of underlying Alzheimer’s pathology. The 
degree to which the clinical diagnosis truly represents AD is often unclear and AD is, 
in most clinical cases, a diagnosis of exclusion. Therefore, the sensitivity and 
specificity of clinical diagnosis is important when assessing study validity [9, 17]. 
Prodromal stages 
Traditionally, there were no effective treatment options following a diagnosis of AD, 
and therefore it was often made late in the disease course. Recent advances in both 
imaging and CSF analyses have increased the weight of the biomarkers, leaving a 
difference between clinical practice, guidelines, and research and allowing an early 
diagnosis to be made. A prodromal state called mild cognitive impairment (MCI) 
includes patients who are at high risk of developing dementia. The best identifiers of 
a prodromal state are under constant revision with several sub-forms that have been 
reported and suggested. Patients with only subjective cognitive impairment (often 
referred to as SCI) or with established biological markers such as amyloid-PET may 
be included. Recently, patients reporting behavioural symptoms (mild behavioural 
impairment, MBI) has been suggested as a prognostic and important prodromal form, 
which is closely related to our current work [25]. Changes in diagnostic 
classifications based on new methodology with prospective information in patients 
without clinical dementia, have significant ethical and practical consequences 
because disease-modifying treatment is still unavailable. However, this thesis is 




7.2.2 Dementia with Lewy-bodies 
Epidemiology and terms  
DLB was first described in 1961 by Okazaki et al. and was primarily believed to be a 
curiosity [26]. DLB was first proposed as a disease in 1976 and the first diagnostic 
criteria were established in 1996 and updated in 1999, 2005, and 2017 [27, 28]. 
Today, DLB is considered one of the most common causes of dementia and Lewy-
body pathology is also very common (10–60%) in those with ‘mixed dementia’ [13]. 
The exact prevalence and incidence of DLB is unknown, but it is believed to occur in 
1–1.5% of elderly people and clinically constitutes 5% of dementia cases [29]. There 
have been several revisions of the clinical criteria to increase their sensitivity, and 
improved imaging techniques have increased the estimates and allowed physicians to 
make earlier diagnoses. The comparative incidence of diagnosed DLB to other 
neurodegenerative diseases may be higher in wealthy parts of the world but the 
suggested geographical differences may also be associated with other factors [27].  
Parkinson’s disease dementia (PDD) is closely related and is pathologically not 
differentiable from DLB, and only clinically separated by the relative order of motor 
symptoms (occur first in PDD) or memory symptoms (which occur first in DLB). 
PDD and DLB are suggested to represent aspects of a disease continuum and share 
important common underlying molecular pathogenesis. However, they differ in the 
pathological spreading patterns and scientists argue that there remains a pressing need 
to differentiate between the mechanisms of the two syndromes [30]. The current 
thesis uses both the terms Lewy-body dementia (LBD, including DLB and PDD) and 
dementia with Lewy-bodies (DLB, not including PDD).  
Pathology 
Lewy bodies are named after Dr. Friederich Lewy, a German neurologist. In 1912, he 
discovered abnormal protein deposits that disrupt the brain’s normal function in 
people with Parkinson’s disease, and these deposits were later called Lewy bodies. 
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The characteristic alpha-synuclein lesions form into aggregates inside neurons, 
becoming immunopositive with anti-alpha-synuclein antibodies [31]. Such lesions are 
increasingly common with age, and they are also present in healthy elderly people. 
The neuropathology is staged according to several different staging systems that are 
used in parallel in diagnostic practice. One staging scale that is used to describe co-
morbid synuclein pathology in AD is the CERAD scale, which has the following 
stages: no to scarce, moderate, and frequent. The most widely accepted and used 
scale that is used to diagnose DLB is the McKeith criteria. These criteria differentiate 
brainstem, limbic, and diffuse neocortical stages, which are consistent with the 
neuroanatomical spread concept proposed by Braak et al. for alpha-synuclein 
pathology [19, 27].  
Pathogenesis 
The underlying cause of DLB is unknown. The genetic component of DLB is less 
described than in AD and Parkinson’s disease, but shows overlap with both. Both 
DLB and Parkinson’s disease have abnormal alpha-synuclein deposits in the brain, 
but at different locations. In the healthy brain, alpha-synuclein plays several 
important roles in neurons, especially at the synapses. Abnormal alpha-synuclein 
processing causes synapses and neurons to work less effectively, and eventually leads 
to synapse loss and neuronal death. The result is widespread damage to the function 
of specific brain regions and a decline in abilities that are controlled by those brain 
regions. Escalation of alpha-synuclein pathology distribution was suggested to result 
from a prion-like effect with propagation of pathology between the cells [32]. 
Clinical features 
The first description of DLB in 1961 reported the concurrent development of 
progressive cognitive decline with fluctuating attention, motor symptoms 
(parkinsonism), and visual hallucinations, which are part of the core clinical 
syndrome. Rapid eye movement (REM) sleep behaviour disorder, which is recurrent 
dream enactment behaviour that includes movements mimicking the dream content, 
was later included as core symptom. All the major symptoms place a considerable 
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burden on carers. These symptoms combined with a more rapid disease progression 
create a large clinical challenge.  
Biomarkers 
The most frequently used marker for distinguishing DLB from AD is well-established 
dopamine transport imaging (DaT-Scan) with a sensitivity of 78% and a specificity of 
90%. This method was primarily developed for Parkinson’s disease and focused on 
the loss of dopaminergic neurons in the substantia nigra. Normal DAT uptake may be 
reported in autopsy-confirmed DLB either because of minimal brainstem 
involvement and limited nigral neuron loss or a balanced loss of dopamine across the 
whole striatum, rather than predominantly in the putamen. Other strong biomarkers 
are reduced uptake on metaiodobenzylguanidine myocardial scintigraphy and 
polysomnographic confirmed REM sleep disturbance without atonia. More 
supportive biomarkers are relative preservation of the medial temporal lobe structures 
on CT and MRI, hypoperfusion/metabolism in the occipital cortex on FDG-PET, and 
characteristic EEG changes. Reduced CSF alpha-synuclein has been reported but is 
not yet available as a biomarker in clinical practice. The most recent DLB criteria 
revisions supported the importance of using biological markers to increase the 
accuracy of the DLB diagnosis [27].  
Possible, probable, and definitive diagnosis 
Clinically, DLB is diagnosed as probable or possible based on the certainty of the 
diagnosis. Probable DLB has two of four core clinical symptoms, or one of four 
symptoms with abnormal indicative markers (i.e. DaT-Scan, myocardial IBG-
scintigraphy, or polysomnography). Possible DLB can be diagnosed with one core 
symptom (but no indicative markers), or one or more indicative markers (without a 
core symptom).  
The definitive DLB diagnosis is neuropathological and is based on the localisation of 
alpha-synuclein pathology in neocortical and limbic regions, as well as the brainstem, 
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amygdala, and olfactory bulb. With the high comorbidity risk of AD pathology, these 
findings are cross-examined with the likelihood of the presence of AD [27].  
Prodromal stage 
Current efforts are focused on developing criteria for prodromal DLB stages, using 
both clinical features such as loss of olfactory function, restless legs, RBD, 
autonomic dysfunction, frequent delirium episodes, and more specific 
neuropsychological tests of executive and visuospatial functions. Alpha-synuclein 
PET ligands are in development, and artificial intelligence and machine learning have 
been successfully used in the EEG analyses [33, 34].  
7.2.3 Other dementias 
Vascular dementia 
Vascular dementia is responsible for approximately 10–20% of dementia cases, but 
because of the life-style risk factors in vascular disease and large differences in 
sensitivity in the diagnostic methods, the incidence is highly variable. Vascular 
dementia may arise as a sequel to any form of cerebrovascular disease, including both 
large haemorrhagic events and chronic ischaemia. The most common vascular 
contributor to dementia is cerebral small vessel disease. Small vessel disease is most 
often diagnosed using radiological methods but refers to several different changes in 
brain microvessels in the cortical and subcortical matter. 
The diagnosis is based on a temporal relationship between the presence of focal signs 
on a neurologic examination and evidence of vascular damage on brain imaging in 
accordance with the National Institute of Neurological Disorders and Stroke (NINDS) 
criteria [35]. Three clinical features are necessary to diagnose probable vascular 
dementia, which are: (1) acute onset of dementia, demonstrated by impairment of 
memory and two other cognitive domains, such as orientation, praxis, or executive 
dysfunction; (2) relevant neuroimaging evidence of cerebrovascular lesions; and (3) 
evidence of a temporal relationship between stroke and cognitive loss [35, 36]. A 
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definitive diagnosis of vascular dementia requires neuropathological examination 
with the absence of neurofibrillary tangles and neuritic plaques, exceeding those 
expected for age, and an absence of other conditions that are associated with 
dementia [37]. 
Many patients with vascular dementia will not have episodic memory deficits, 
particularly in the early stages. They predominantly develop frontal dysexecutive 
syndrome [36].  
Frontotemporal dementia  
Frontotemporal dementia or frontotemporal lobar degeneration (FTLD) is a 
heterogeneous group of disorders with distinct psychiatric and psychological 
symptomology.  
There are three clinical syndromes with different symptoms, progression, and 
underlying pathology, although there is overlap. The most common clinical syndrome 
that accounts for more than half of the cases is the behavioural variant frontotemporal 
dementia, which is characterised by social disinhibition, apathy, and emotional 
blunting, and it is associated with atrophy of the frontal and anterior temporal lobes. 
A second, less common, clinical syndrome is semantic dementia, which is 
characterised by an impaired understanding of the meaning of words, faces, objects, 
and other sensory stimuli. The patients with predominantly left‐sided atrophy have 
particular difficulty understanding words whereas right‐predominant patients show 
difficulties in face recognition. The third clinical syndrome, termed progressive non‐
fluent aphasia, is typically characterised by effortful speech and impaired use of 
grammar [38]. 
These patients show neuropathological similarities to other degenerative diseases 
such as amyotrophic lateral sclerosis with nuclear factor (TDP-43) that presents with 
non-physiologically fibrils and granules. Because of differences in age, clinical 
progression, and symptoms, these patients are often studied separately. 
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Frontotemporal-like pathology and TDP-43 aggregation are also found to some 
degree in many AD and DLB patients [17, 38]. 
Mixed dementia 
Many different pathologies are associated with increasing age, and thus, there is a 
naturally increasing co-morbidity with age. A mixed cause of dementia is common, 
and AD pathology, especially, is often combined with some degree of vascular and 
Lewy-body pathology [12].  
Several dementia disease pathologies are also more often associated with each other, 
when the shared risk factors of time and somatic co-morbidity are taken into 
consideration. Vascular damage is very common in elderly people and some degree 
of cerebrovascular disease is seen in most patients with dementia. As a comorbid 
condition, cerebrovascular disease may worsen the dementia because of other causes 
such as AD and DLB. This is consistent with the cognitive reserve model, suggesting 
that the combined pressure of neurodegenerative and vascular pathologies increases 
the risk of mixed dementia in an aging population. The prevalence of mixed dementia 
is, therefore, often discussed as a continuum of causes, which is also supported by 
genetic results [23]. However, there are pathological data showing a different disease 
trajectory based on the type of dementia rather than the overall pathology load, 
suggesting a threshold of importance. Differentiation between AD and vascular 
dementia has received the most attention [39].   
Dementia caused by excessive use of alcohol is also a prevalent cause, and it is highly 
co-morbid with other risks of dementia and poor physical health. Additionally, drugs 
such as benzodiazepines, morphine, and central stimulants such as amphetamine will 
probably become a more common part of the dementia pathogenesis process with 
increased illicit use. There are also more uncommon causes of dementia, ranging 




7.3 Neuropsychiatric symptoms 
The psychological and behavioural changes in dementia covers a wide range of 
symptoms. Some symptoms are mood-like, such depression, euphoria, apathy and 
anxiety. Other symptoms are more hyperactivity-like, such as irritability, 
disinhibition, wandering, and aggression, which are often separated from psychotic 
symptoms such as hallucination and delusions. However, there is a large clinical 
overlap between symptoms.  
However, the importance in diagnostics and management has been relatively 
neglected for decades, with a focus on the cognitive decline and especially amnestic 
memory [41]. The clinical optimism that is based on imaging and biomarkers 
reinforces this effect because the cognitive decline is more persuasively associated 
with the test results. However, the burden of NPS in dementia on the quality of life 
for both patients and carers is as least as high as the burden that results from loss of 
daily activity (e.g. washing, dressing, ability to be alone) and cognitive disabilities 
[42]. 
Awareness is increasing about the important role that NPS play in the dementia 
disease burden. NPS are highly associated with time of admission to institutionalised 
care [43], and are associated with excess morbidity and mortality, longer hospital 
stays, and higher overall cost of dementia care [44, 45]. Carers are important, and 
they are also severely affected by stress, depression, and reduced carer income [46]. 
Eventually, the carers’ own health and quality of life is at risk [47]. Clinically 
significant NPS are associated with more rapid disease progression [48]. Therefore, 
improved management of NPS may have the potential to modify the disease course, 
lower costs, and improve the quality of life for patients and carers [43, 49]. 
Definition 
The definition of NPS has suffered from imprecise nomenclature. Different 
designations such as non-cognitive symptoms, behavioural and psychological 
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symptoms (often abbreviated BPSD), and neuropsychiatric symptoms (NPS) are 
commonly used. The current work uses NPS to highlight the combined psychiatric 
and presumed neurological aspects. NPS is also the most frequently used term in 
research, with 1611 (NPS in full) references compared to 438 (BPSD in full) 
references when cross-searched with ‘dementia’ in PubMed, among 110118 total 
references. 
 
Figure 2. NPI (Neuropsychiatric Inventory), Cache County study (presented later); 
NPS-PIA (Neuropsychiatric Syndromes of AD Professional Interest Area [NPS-PIA]) 
from the International Society to Advance Alzheimer’s Research and Treatment 
(ISTAART), which presented the Mild Behavioural Impairment (MBI) criteria [50]. 
In 2008, based on studies from 2007, the FDA issued a black-box warning on the use 
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Neuropsychiatric symptom rating-scales  
The Neuropsychiatric Inventory (NPI) has increased in scientific popularity since it 
was first introduced by Cummings in 1994. The NPI includes an interview with a 
carer (either family or professional) about 12 symptoms, and it scores the severity and 
frequency of all symptoms. It provides a symptom item score (0–12) and an NPI total 
score (0–144). NPI is popular in dementia research and several other diseases that are 
associated with psychiatric symptoms [51]. The wide range of symptoms, and ease of 
administration has made it a commonly used clinical instrument. The NPS interest 
group (NPS-PIA) at the Alzheimer’s Association has designated the NPI the gold 
standard [52]. Many reviews and meta-analyses that only include studies using NPI 
also consolidate the role of NPI in research. Additionally, many spin-off versions 
have been introduced, such as the NPI-questionnaire (NPI-Q) and the nursing home 
edition. The symptoms are described in Table 1.   
With an increasing focus on NPS, several different scales have been developed such 
as the Behaviour Rating Scale for Dementia of the Consortium to Establish a Registry 
for Alzheimer’s Disease (BEHAVE-AD), the Cambridge Examination for Mental 
Disorders of the Elderly (CAMCOG), the Brief Psychiatric Rating Scale (BPRS), the 
Psychogeriatric Dependency Rating Scale (PDRS), and the Present Behavioural 
Examination (PBE). None of these scales have shown better validity in describing 
symptoms or have been introduced in clinical practice to the same extent as the NPI 
[25, 52-54]. The NPI covers a wide range of symptoms and may not have the strength 
of more specific scales such as the Cohen-Mansfield Agitation Inventory (CMAI) or 
instruments that selectively measure apathy or depression. The strengths and 




7.3.2 Frequency of neuropsychiatric symptoms 
Although not obligatory in dementia, most studies report that NPS are present in 
nearly all patients when they are assessed repeatedly. The frequency reports vary 
considerably between studies, but there are also large differences in methodology, 
case selection, and assessment procedures. Apathy is the most common symptom, 
while other symptoms vary in frequency but are rarely reported in fewer than 10% of 
patients (with exception of elation/euphoria) [55, 56].  
There are several reviews and meta-analyses that are dedicated to the frequency and 
persistency of NPS, with the most recent comprehensive work by van der Linde et al. 
(2016), which is the sixth revision of their meta-data (Table 1 also shown in the 
Discussion in Figure 5) [55]. They analysed data from 59 prospective longitudinal 
studies (3 months long or more) to determine the incidence and persistence of NPS, 
which are called behavioural and psychological symptoms, although most studies 
used the NPI. The studies were mostly from population-based or general practice 
with only eight studies from nursing homes. Using the baseline prevalence scores, 
they found that NPS were more frequent in younger patients, moderate to moderate-
severe dementia patients, and those recruited from psychiatric settings. The meta-
analysis points out the high variability between studies and emphasises the need for 
more long-term studies, primarily in home-care settings [55]. 
Nursing home studies focusing on NPS were systematically reviewed by Selbæk et 
al. [56]. Selbæk et al. also conducted meta-analysis using a weighted mean score of a 
wide range of NPS from 28 articles including 8486 nursing home residents, with 
seven studies and 1458 residents having longitudinal assessment (Table 1 and Figure 
5). The residents had all-cause dementia, the mean age was 83 years, and 73% were 
women. Their analysis included an NPI item score ≥4, and their prevalence rate for 
any NPS was 82%. This longitudinal review shows that NPS are stable or decrease 
after admission to nursing homes, which is contrary to the results obtained from 
cross-sectional studies that report a greater prevalence of most NPS in moderate or 
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severe stages of dementia than in mild dementia. They also pinpoint the diversity of 
the study population and the need for studies with a duration longer than 2 years [56]. 
  
 
Table 1.  The description is based on key features from the NPI (Cummings) and the 
prevalence and persistency scores are presented from Van der Linde et al. and 
Selbæk et al. [55, 56]. 
  




Selbeak et al 
Persistency 
(%) Linde et al
Persistency (%) 
Selbaek et al
1 Delusions False beliefs, stealing or harm Moderate 
(9-40)
22                  Low 
(0-52)
13-66









Resistive to help from others at 
times, or hard to handle
High
(18-87)
30                  Moderate 
(21-77)
53-75
4 Depression Seem sad or say that their depressed High 
(8-57)




Upset when separated, nervousness, 
sighing, unable to relax, excessively 
tense 
High 
(17-52) 21                  
Moderate 
(17-52)












Act impulsively, talks to strangers or 
saying hurtfull things 18                  10-79
9 Irritability
Impatient, cranky, difficulty coping 
with delays or waiting
High 







Repetitive activties, pacing, restless 




Night awakening, too early mornings 





12 Eating Lost or gained weight, change in food 
preferances
Total NPI Sum of item scores 79                  
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7.3.3 Persistency of neuropsychiatric symptoms  
The course of a symptom is most often reported as persistency over a given time 
period (i.e. risk of having the symptom at a second assessment if it is present at the 
first assessment). A recent meta-analysis concluded that many NPS are persistent, but 
with large differences between the symptoms (Table 1) [55]. Several other reviews on 
general NPS management and treatment describe the longitudinal course of NPS 
broadly as fluctuating or persistent  [50, 52, 53, 56, 57].  
Consistent with meta-analysis and systematic reviews, apathy is the most persistent 
symptom, while other affective symptoms (anxiety, depression) are less persistent. 
Even a high frequency symptom like apathy shows large variability between studies 
(10–55%). The two studies showing high symptom persistency have different 
designs, cohort selection, and time between assessments, but both use the NPI as a 
rating scale. Van der Linde et al. rate wandering (similar to aberrant motor behaviour) 
as also highly persistent, while Selbæk et al. rate agitation/aggression as persistent.  
The studies that are included in the reviews are very different. The duration of 
observation varies; most studies lasted for 3–6 months, and few had more than four 
follow-up visits. Because patients with dementia have high mortality and co-




7.3.4 Individual patient’s course  
Studies on the long-term course of NPS are often reduced to the discussed persistency 
levels as mean scores or proportions at two different observation points. Thus, they 
do not provide information about an individual patient’s long-term course.  
One of the few studies describing an individual patient’s long-term course is a 9-year 
study with assessments every 4 months by Hope el al., who reported that most 
patients had persistent symptoms until death or single symptom episodes [58]. A 
relapsing-remitting pattern was less common. Fewer than 14% of people who rated 
positively had more than a single episode. They also argued that the data did support 
the view that behavioural and psychiatric changes occur predominantly in a late stage 
of the dementing illness.  
However, other studies report a low persistency over 18 months and four 
assessments, and except for apathy (13%), no symptom on the NPI had greater than 
10% persistency, but there was a higher incidence of new symptoms [59]. Additional 
selected studies on single symptoms report that wandering or agitation occurs most 
frequently in three of four consecutive visits over 2 years, while paranoid delusions 
and hallucinations occurred intermediately, and depressed mood with vegetative signs 
were rarely persistent [60]. A recent study reported an equal distribution between 




7.3.5 NPS according to dementia type  
There are relatively few longitudinal studies of NPS besides all-cause dementia or 
AD, and the existing studies have small study populations. The degree of diagnostic 
accuracy is different in the studies, but some studies report non-AD as a comparison. 
The European Alzheimer Disease Consortium’s meta-analysis of 2,808 patients 
reported no significant difference between dementia diagnoses in a cross-sectional 
study [62].  
Few studies have especially aimed at describing the differences between NPS in DLB 
and AD, and very few had a longer follow-up. A Japanese multicentre-study of 1091 
AD and 249 DLB patients based on admission assessments showed a higher 
prevalence and more severe NPS in DLB than in AD patients [63]. This is consistent 
with data from our Demvest study, which also shows a higher baseline frequency of 
symptoms and more severe hallucinations and apathy in DLB compared to AD 
patients [64]. A large Taiwanese study reported more frequent and more severe 
depression in DLB compared to AD patients using the DSM‐IV diagnosis, with the 
largest difference in symptoms such as anhedonia and fatigue in a mild dementia 
population [65].  
NPS in vascular dementia is also less studied. Single studies found few differences, 
except for more sleep disturbances, in vascular dementia compared to AD patients 
[66]. Similarly, others found that vascular dementia patients had significantly more 
agitation and sleep disturbances than AD patients [67].  
Patients with frontotemporal dementia diseases show personality and behavioural 
changes that are important diagnostic features. The many different underlying 
pathological mechanisms that produce diverse behavioural variants. Aggression is 
often reported, and management is an important clinical issue because of the 
combination of disinhibition and aggression. Although previously thought to be rare, 
it is now recognised that some behavioural variants in frontotemporal dementia 
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patients include psychotic symptoms, which are common (20–40%) but there is a 
large difference between sub-types [68].  
Alcohol-related dementia is understudied, especially the NPS. Apathy is reported to 
be more prevalent in this group. These patients are also prone to high co-morbidity of 
somatic or psychiatric symptoms, which increases the frequency and persistency of 
NPS [69]. 
7.3.6 Pathogenesis 
The underlying mechanism of psychiatric symptoms has been hard to determine, even 
with advances in genetic analysis. The relevance of biological findings from primary 
psychiatric disorders such as depression has also failed to be reproduced in elderly 
people.  
Pathological studies report more severe pathology in those parts of the brain with 
corresponding importance to the normal behavioural and emotional regulation 
functions, such as limbic structures and the prefrontal cortices [53, 61]. Patients with 
agitation have more pronounced pathology in cortex-thalamic circuitry that is 
involved in emotional regulation [52]. Depression is associated with higher total 
pathology scores and with lower serotonin receptor and transporter binding levels. 
Apathy has been associated with more temporal cortex atrophy, as well as 
hypoperfusion and hypometabolism in these areas. These findings highlight the 
biological nature of NPS and the possibility of developing treatment options [53]. 
The high degree of plasticity even in old age also raises the questions whether some 





NPS management has received much attention because many approaches have been 
found to be ineffective or have a high risk of adverse side effects. The clinical 
guidelines and scientific reviews agree that the best treatment option for NPS is 
structured individualised dementia care with psychological, social, and environmental 
interventions [43, 71, 72]. Therapeutic methods based on capturing the patient’s 
engagement is important [73]. A wide variety of different approaches exist, supported 
by evidence suggesting that variation exists in the effect size between the various 
strategies. Many non-pharmacological interventions are costly in long-term care but 
some of these interventions have been shown to be cost-effective [49, 72].      
International scientific and government guidelines are restrictive in the use of 
psychopharmacological interventions and especially antipsychotics because the risk 
of side effects often outweighs the benefits. For depression and anxiety, 
antidepressants can be routinely prescribed. The use of anti-depressants for 
depression and anxiety is primarily recommend for those with previous depression 
and especially those who experienced previous effects of medication [23]. Citalopram 
has shown some effect on aggression, especially in frontotemporal dementia [74]. 
The use of melatonin and benzodiazepines for sleep problems is also discouraged 
[75].  
The effectiveness of antipsychotics is under scrutiny because of serious adverse 
effects and for ethical reasons related to a lack of consent and therapeutic sedation. 
Antipsychotics are still frequently used for both aggression and psychotic symptoms 
because there are no other effective medications. Therefore, the pharmacological 
treatment of agitation/aggression and psychotic symptoms are secondary to non-
pharmacological interventions. The suggested indication for antipsychotics is 
consistently the risk of harm to patients or carers. There are differences in guidelines 
whether there is severe distress including symptoms of agitation, hallucinations, or 
delusions (NICE, UK), while in the Norwegian guidelines, only severe distress with 
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symptoms of aggression should be considered an indication for antipsychotic drug 
treatment [75]. A small dose of risperidone (0.5–1 mg) to treat severe psychosis in 
dementia is the only approved treatment, and it is only approved for up to 6 weeks. 
The Norwegian national guidelines suggest olanzapine and aripiprazole as secondary 
choices, but consistent with the UK guidelines, they emphasise the need for 
structured assessments and thorough discussion with the patient and family. The gap 
between theory and practice of prescribing antipsychotics is heavily debated, and 
their use has decreased in elderly patients. Risperidone is not approved for dementia 
by the US Food and Drug Administration (FDA). Other nonapproved treatments are 
sometimes suggested but there is no sufficient evidence to use these in clinical 
settings unless there are other intervention points, such as diabetic neuropathy or 
epilepsy.  
Treatment of DLB is also more difficult because of the patients’ sensitivity to anti-
psychotic drugs. Donepezil and rivastigmine, which are acetylcholinesterase 
inhibitors, may be effective in treating hallucinations in DLB patients, while other 
similar drugs and anti-depressants have shown no effect [76]. 
Both the symptoms and treatments are costly to society and a great burden to patients, 
carers, and health professionals. The limited understanding of the underlying 
mechanism is one of the reasons that no major advances in pharmacotherapy have 







7.4 Psychotic symptoms 
Psychotic symptoms in dementia include hallucinations or delusions, although more 
complex symptomology such as thought disorganisation, misidentification, and 
conflicted self-identity also occur. The latter symptoms may be harder to identify in 
patients with dementia. Previously assumed to be uncommon or present late in 
dementia, psychotic symptoms are now recognised earlier in dementia and in non-
demented/healthy elderly [77, 78]. Several studies have shown an overlap between 
late onset schizophrenia and early psychotic symptoms in dementia. This thesis 
includes hallucination and delusions as psychotic symptoms, which is consistent with 
most reviews on NPS and focuses on people diagnosed with dementia. 
Patients are typically able to report these experiences when specifically asked, as are 
observant caregivers. Patient responses to their hallucinations vary both in their 
degree of insight and emotional reaction to them. Psychotic symptoms are often 
frightening and stigmatising. Patients and carers are afraid to tell others because there 
are legal consequences and patients worry about being institutionalised. Psychotic 
symptoms are often associated with agitation/aggression, and together they represent 
a large part of the burden of dementia disease, both emotionally and economically.     
Hallucinations  
Hallucinations are any form of false sensory experiences and can be from any of our 
senses: vision, hearing, touch, taste, or smell. Visual hallucinations are the most 
common form of hallucinations, and they are especially common in DLB patients. 
These hallucinations are typically well-formed and can feature people, children, or 
animals. Auditory hallucinations (speech or sounds of music) are usually less 
organised than those observed in schizophrenia. Olfactory hallucinations are 
uncommon and are often associated with other diseases such as stroke or brain 
tumour. Tactile hallucination with feeling of things crawling inside or outside one’s 




Delusions are beliefs or impression that are maintained despite being contradicted by 
reality or rational argument. Symptoms may also be more complex with false 
memories of events or false or bizarre beliefs. The nature of such symptoms is 
subjective, and thus, clinical assessment is essential. Patients are blind to their 
symptoms, and thus, they do not seek help directly because of the symptoms, but 
rather they experience the consequences of the delusions. Information from next-of-
kin is essential. This is especially important for elderly people because these 
symptoms are often less invasive. 
7.4.2 Frequency 
Reviews estimate that 18% of dementia patients experience psychotic symptoms, but 
studies with a longer follow-up time have reported higher estimates. In the cohort 
from Hope et al., 45% reported persecutory ideas and 25% reported hallucination (co-
occurrence was not reported). Recurrent, complex visual hallucinations occur in up to 
80% of patients with DLB and are a core symptom of that diagnosis [27]. The 
prevalence of hallucination in AD is more uncertain, with studies reporting a 
prevalence rate as low as 1% and others reporting a rate of more than 50%. Delusions 
are reported more commonly than hallucination in AD, but there is no clear 
difference between AD and DLB. One study reported subclass delusional 
misidentification to be common in DLB whereas paranoid delusions were associated 
with AD [79].  
7.4.3 Course 
For all dementia patients, psychotic symptoms were reported with a low persistency 
(below 30%) by van der Linde et al. [55]. However, there are large differences 
between the studies. Ballard et al. (1997) reported psychotic symptoms as brief or 
persistent, with few having an intermediary course [80]. Hallucinations are reported 
with a higher stability compared to delusions [55, 58, 81]. Hallucination seem to be 
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more persistent in DLB than in AD [80]. The differences in both frequency and 
course between studies are likely related to differences in the cohorts such as type and 
stage of dementia and the care settings, as well as use of different rating scales. 
7.4.4 Pathological mechanisms 
Several cohorts demonstrate familial aggregation of psychosis in AD, and studies also 
indicate association with psychotic diseases within families, indicating a genetic 
contribution  [82, 83]. Patients with previous psychotic episodes or with first degree 
relatives with psychosis have a higher risk of severe NPS [84]. Using a polygenic risk 
score, which is a method to analyse the combined effects of many genes on the 
increased risk, Creese et al. showed a link between AD psychosis and primary 
schizophrenia [85]. Although care should be taken regarding the validity of negative 
results, there are is no evidence that genetic variants that increase the risk of AD also 
predict psychotic symptoms, which suggests that psychotic symptoms are secondary 
to a more severe dementia disease.  
While no single specific brain area has been identified as responsible for psychosis 
symptoms, both imaging and post-mortem neuropathological studies suggest that tau 
levels are increased in the dorsolateral prefrontal cortex of AD patients with 
psychosis compared to AD patients without psychosis, rather than in the entorhinal 
cortex or hippocampus [86]. The severity of pathological changes does not seem to be 
of major importance, but these studies are difficult to interpret because of the risk of 
selection bias, differences in the time from psychotic symptoms to death, and the 
varying degree of psychotic symptomology. 
Having mixed dementia with two or more pathological changes has been suggested as 
a risk factor for psychosis as a variant of the total load hypothesis. Studies have 
reported higher levels of delusion, hallucinations, and aberrant motor behaviour in 
patients with both LBD and AD pathologies [87, 88], but other contradictory findings 
exist [79, 89]. Other studies report differences between AD and LBD, such as 
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reduced occipital metabolism in DLB patients was found to be associated with the 
frequency and severity of visual hallucinations but not in AD [90]. 
Psychotic symptoms were found to be associated with cerebrovascular disease such 
as small vessel disease and subcortical arteriosclerotic leukoencephalopathy [91]. 
Small vessel disease has been associated with depression in elderly patients, but few 
studies have addressed its associations with psychotic symptoms.  
A small MRI study showed increased vascular disease in eight patients with late 
onset schizophrenia, and a recent study in young psychotic patients shows 
microvascular abnormality changes on MRI, which supports vascular dysfunction as 
a contributing factor to psychosis [92, 93]. The vascular components in psychosis in 
the elderly need to be further validated, and especially in those with severe psychotic 
symptoms in early dementia. 
7.4.5 Cerebral amyloid angiopathy 
A specific form of vascular pathology, cerebral amyloid angiopathy (CAA), is 
defined as deposits of amyloid in the vessel walls, which may lead to necrotic lesions 
with an increased risk of haemorrhage and a smaller lumen with reduced perfusion. 
Age is the largest known risk factor for CAA, and it is very common in most elderly 
people (80–90 years), with 20–40% occurring in non-demented and 50–60% 
occurring in demented patients who showed post-mortem CAA [16, 94].  
The neuropsychological profile of both CAA and small vessel disease in patients 
without clinical dementia shows decreased processing speed [94]. Dementia is not 
directly associated with processing speed, but psychotic diseases are associated with 
processing speed [95]. Vascular pathology and reduced information processing speed 
may be modifiable risk factors of psychosis in dementia, and thus, to some extent, it 




With improved radiological techniques, the focus on CAA is increasing, and the risk 
of spontaneous lobar haemorrhage and transient focal neurological episodes 
(‘amyloid spells’) are important [96]. CAA contributes to neurodegeneration, but its 
relationship to clinical symptoms and the course of dementia is not fully understood 
[16]. 
The mechanisms underlying accumulation of β-amyloid in arterioles is unclear. It is 
unknown whether the deposition of β-amyloid in the vessel wall originates from the 
central nervous system and accumulates because of reduced perivascular drainage or 
if it is produced and deposited locally by vascular smooth muscle cells. Circulating 
amyloid beta peptide may also bind to the receptor for advanced glycation end-
products in endothelial cells and then be transported through the blood-brain barrier 
into brain [16]. 
Studies have shown an association between MRI-diagnosed microbleeds that may 
represent CAA and neuropsychiatric symptoms, but not psychosis, in non-demented 
elderly patients [97]. CAA, either as a post-mortem finding or identified using more 
precise radiological markers of CAA, has rarely been studied and an associated 







Describe the frequency, course, and neuropathology of NPS in people with mild 




1) Profile the frequency and associated variables of each NPS over 5 years in 
patients with mild dementia, and report NPS in patients with AD and LBD 
separately. 
 
2) Describe the longitudinal course of NPS in individual patients with AD and 
LDB from diagnosis to death. 
 
3) Investigate the post-mortem pathological correlates of severe psychotic 
symptoms in AD and LBD patients who were followed annually from the time 
of diagnosis until death. 
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9. Methodological considerations 
9.1 Validity of the Demvest study 
All three articles are based on data collected from participants in the Demvest study. 
The study started enrolling people with mild dementia in 2005 and it is a prospective 
longitudinal cohort multicentre study of patients with a clinicopathological diagnosis. 
A more detailed technical methodological description is enclosed as supplementary 
information.  
Demvest researchers have published baseline (cross-sectional), short-term, and long-
term longitudinal data. The Demvest cohort has been investigated in several projects 
and articles, both as independent and aggregated data materials. It is ongoing after 15 
years, during which time there have been changes in the diagnostic criteria, the use of 
supplementary diagnostics, and the use of biomarkers in clinical practice to diagnose 





9.1.1 Strengths  
Follow-up time 
Compared to most other studies, the Demvest study has a very long follow‐up time. 
Annual assessments are conducted using structured instruments, and the high level of 
data completeness (except for attrition because of death) are additional strengths 
because the bias introduced by selective attrition is likely small. Repeated 
measurements with a high follow-up rate allow for persistency and reoccurrence 
analyses of mild to severe dementia. 
Low attrition  
The Norwegian health care system has a common electronic data system, few 
specialised clinics working with dementia, and a public with a high participation rate 
in similar studies [98]. Study participation was integrated into clinical management. 
With 98% data completeness for the possible assessments, this study is unique. This 
also means that many patients with vascular events, hip fractures, and cancer 
(diagnosed after inclusion) are included. Although this creates the risk of 
camouflaging the true effect of dementia, our evaluation is that these are integral 
parts of dementia diseases and they are, thus, relevant to the aim of this thesis, which 








A high diagnostic accuracy was demonstrated in the 56 patients with a 
neuropathological diagnosis. In the current cohort, we were able to correctly identify 
and diagnose 16 of 20 patients with neuropathologically verified DLB, resulting in a 
sensitivity and a specificity for probable DLB alone of 73% and 93%, respectively. 
The sensitivity, specificity, positive predictive value, and negative predictive value 
for a clinical diagnosis of probable AD, including the two mixed diagnoses, were 
81%, 88%, 89%, and 79%, respectively [99].  
With improving clinical diagnostics and changes in clinical diagnostic criteria, we 
have, therefore, chosen to use the final diagnoses based on all known information, 
including post-mortem findings now up to 65 patients. 
Hope et al. reported data from pathologically diagnosed patients separately, but no 
other long-term prospective studies reporting on a wide range of NPS have 
pathologically confirmed diagnoses [58]. The use of a pathological diagnosis and 
accurate diagnostic tests ensures that results are valid even with changing clinical 
diagnostic criteria. Repeated diagnostic assessments in patients with diagnostic 
uncertainty is part of ordinary clinical management.    
 
 




This is one of the largest long‐term studies of LBD including the 38 patients from the 
extended inclusion period. In article 1, we used the originally recruited all-cause 
dementia patients as the mild dementia cohort. There is a high percentage of patients 
with DLB who are also in the initially recruited patient group. Our DLB prevalence 
in this sub-cohort is comparable to epidemiological studies by applying stringent 
methodology to detect DLB, according to the original criteria [27, 100]. Most patients 
with suspected DLB had a DaT-Scan, which might have yielded more patients with 
DLB than in other comparable cohorts. Finally, we did not have access to cardiac 
scintigraphy, which has demonstrated high sensitivity for diagnosing DLB [27], or 
polysomngraphy to secure the RBD diagnosis, both of which were recently included 
as ‘indicative biomarkers for DLB’ together with a DaT-Scan.     
Comprehensive diagnostic procedures are costly and time-consuming, other studies 
like Brodaty et al. [84] with 3% DLB did not use such diagnostic strategies, and thus, 
DLB may be underdiagnosed or have a negative selection bias resulting from DLB 
patients with a shorter duration of mild-to-moderate dementia before being 
institutionalised or passing away. Studies that included neuropathological diagnostics 
include more similar DLB percentages in the clinical cohorts (21%) [12, 91]. DLB is 
also highly associated with age, and the inclusion of people with mild dementia (as 
defined) may have increased the selection bias because the MMSE is less sensitive to 
the cognitive decline that is associated with DLB than that in AD.  
9.1.2 Limitations 
Recruitment bias 
Our data may have potential recruitment bias because of referrals from primary care 
physicians, which may have led to an increased number of patients with complicated 
dementia or NPS in this clinical cohort [12]. Inclusion based on psychiatric services 
have shown a higher frequency and severity of NPS. However, primary care 
physicians were invited to refer any patients with suspected dementia, and patients 
46 
 
were included from psychiatric, neurologic, and geriatric clinics. We had a low 
number of alcohol-related dementia patients and a low number of fronto-temporal 
dementia patients. The exclusion criterion of no severe somatic or neurological 
illnesses may have excluded some of these patients. Most inclusion and clinical 
assessments were performed by geriatricians and geriatrics nurses, and not 
psychiatric personnel. There were bi-annual meetings of study personnel who were 
involved in the study during the first 10 years to ensure similar evaluation of 
symptoms.  
The high life expectancy and low rate of poverty in adults have probably affected the 
recruitment base towards more patients with DLB and less with vascular dementia 
but with cerebrovascular disease. Because most dementia patients are unable to travel 
by themselves, there are also some patients with involved family carers. The national 
focus of a self-reliant and important primary care health service may have led to the 
recruitment of more complicated cases.  
The current cohort represents to a very high degree a generation of ethnic 
Norwegians, with a large proportion of patients born, living, and dying in a 
geographically small area. Mono-ethnicity may not be a limitation, but it must be 
addressed when assessing the wider clinical application of the findings and may 
strengthen internal stability. We have very high stability of adherence to the hospital 
to which the patients are geographically assigned, and this increases the opportunity 
for systematic and longitudinal data collection. The national death registry showed 
that all participants (up to January 1,2017) died in the western part of Norway (our 
catchment area).    
Dementia definition at inclusion 
Mild dementia was defined as a clinical dementia rating scale (CDR) score of 1 or a 
MMSE score of 20 or more. The MMSE is language and memory dominant, and 
thus, it is less sensitive to the earliest changes in the LBD patients, which included 
both PDD and DLB patients, although the sensitivity of MMSE is comparable to 
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other screening instruments when approaching moderate dementia levels. Our 
definition may, therefore, have selected more progressed DLB patients compared to 
AD patients. Although the term mild dementia is imprecise, this definition is used in 
many studies and represents a group of patients who are often in contact with health 
services because they have a definite disability but are still living at home.   
Non-pharmacological treatments 
Because of the naturalistic design, patients were treated according to the 
recommendations for pharmacological and non-pharmacological treatment, which 
may influence the course of NPS. However, because treatment was not standardised, 
individual treatment differences may have influenced the course of NPS. The patients 
included were followed as out-patients in hospitals and clinics; they received up-to-
date management, and they were also followed after admission to nursing homes. 
Patients may have been provided a more extensive follow-up because they were part 
of the study protocol.  
Pharmacological treatments 
The psychopharmacological interventions received by the participants were likely in 
accordance with national guidelines, which are restrictive regarding use of 
psychopharmacological interventions, particularly antipsychotics. Compared to other 
studies, the prescription levels of antipsychotics were low. At the first follow-up (not 
baseline), 61% used antidementia drugs, 9% used antipsychotics, and 40% used 
antidepressants. Included in these figures were occasional and minor doses that were 
used for sleep difficulties and prochlorperazine that was used as an occasional 
antiemetic (n=6) exclusively accounted for 2.6% of the 9% using antipsychotics.   
In the population-based Cache County study, only 9% of patients used antidementia 
drugs, while 26% used psychotropics. In other comparable studies such as the PRIME 
study, 21% used antipsychotics and in the LASER-AD study, 41% used psychotropic 
drugs [84, 101, 102]. In the Selbæk et al. review, the mean drug use was 69% for 
psychotropics, 32% for antipsychotics, and 31% antidepressants in nursing homes 
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[56]. The restrictive use of psychotropics in the Demvest study is consistent with the 
most recent guidelines. This was probably because of increasing awareness of 
detrimental effects in the elderly, and it was also a caution about the high rate of 
diagnosed DLB patients in our population, who are particularly sensitive to the side 
effects of psychotropic drugs. 
The overall prescription of drugs in the Demvest cohort at inclusion was analysed 
thoroughly. Few patients had potentially inappropriate medications (14%) or 
potentially severe drug–drug interactions (4%), indicating that the prescribing quality 
was acceptable [103]. Thus, the observed poor prognosis in the DLB group is 
unlikely related to the side effects of psychotropics or other drugs. 
Mortality and disease progression 
The cohort had a high mortality rate, particularly the LBD patients, who may have 
confounded the observed course of NPS. The results may be skewed in the direction 
of more DLB patients being assessed closer to the time of death or those with a high 
rate of NPS might have a higher mortality rate, and thus, there is a risk for selective 
drop-out. There is consistent evidence for higher and earlier mortality in DLB 
compared to AD patients [104]. Patients diagnosed with DLB also had nearly 2 years 
less time to nursing home admission than those diagnosed with AD [105]. 
Differences between AD and DLB related to mortality and cognitive decline seen in 
the Demvest study are consistent with meta-analyses [106]. The difference between 
AD and DLB was adjusted using statistical methods described in article 1, which 
included a model where diagnosis of AD/DLB, time, and cognitive decline were 
included. We tried to eliminate the last NPS assessment to adjust for peri-mortem 




9.2 Measurement of NPS 
Extent of use in the thesis  
Assessment of NPS is the key outcome variable in articles 1 and 2, and the key 
defining variable in article 3, all of which were assessed using the NPI.  
9.2.1 Neuropsychiatric Inventory (NPI) 
The validated Norwegian 12-question NPI was used to interview a family member or 
carer [54]. The 12 items are registered as present, and if present, they are scored 
according to their frequency (1–4) and severity (1–3). NPI reports the frequency × 
severity score for individual items that occurred within the last 4 weeks. The NPI 
item score is a product term of two ordinal scales with many of the NPI items scored 
as 0 (reflecting ‘not present’).  
Articles 1 and 2 report if the symptom is present (item score ≥1) and the established 
cut-off item score of ≥4 was a point to determine the clinical significance, which 
includes moderately severe symptoms at a frequency rating of ‘often’ or more 
frequently, and ‘mild symptoms’ that are present at a frequency rating of ‘very 
frequent,’ as previously reported [16, 26]. NPI has a multiplicative scoring system of 
items with a frequency (1–4) and severity (1–3), providing a score of 1, 3, 4, 6, 8, 9, 
or 12. Both the item scores and NPI total score are non-continuous and non-normally 
distributed variables that generate problems when using parametric methods [107]. 
Especially when using advanced statistical analysis with an underlying assumption of 
normal distribution, the large skewed effect with a high number of zeros and lack of 




9.2.2 Psychometric properties 
Content validity 
The NPS categories dysphoria, aggression, aberrant motor behaviour, anxiety, 
delusions, and hallucinations were compared with the affective disturbance, 
aggressiveness, activity disturbances, anxiety and phobia, delusion, and 
hallucinations items from the Behavioral Pathology of Alzheimer’s Disease Rating 
Scale (BEHAVE-AD) and other scales in the primary publication [108]. The NPI 
domain of dysphoria was significantly correlated with the Hamilton Rating Scale for 
Depression (HAM-D). The psychometric properties of the Norwegian version were 
also examined directly compared to the clinicians who rated a patient’s behaviour 
using the same BEHAVE-AD, with equally satisfactory results. The weakest 
correlations were between items assessing affective and anxiety symptoms [54]. The 
NPI has been used as a concurrent validity measure against the revised Cambridge 
Behavioural Inventory to establish its validity in behavioural symptoms in persons 
with dementia in general practice settings [109].  
Internal consistency 
The original study presenting NPI also provided between-rater, test-retest, and 
internal consistency reliabilities, all of which showed high reliability. Cummings et 
al. reported a high level of internal consistency for the overall score as measured by 
Cronbach’s alpha, α=0.88, and that 78% of the scale’s items showed no significant 
relationship with each other, indicating that these items were assessing different 
behaviours [108]. Reviews of NPI reported an α-range of 0.67–0.8 in terms of the 
NPI’s internal consistency, and concluded that overall, the NPI can be said to have 
reasonable to good internal consistency [107]. 
The Norwegian version has reported a similar internal consistency α=0.80. Inter-rater 
reliability was, except for one item, between 0.85 and 1.0 across assessors with 
different levels of health education. The Norwegian version of the NPI is a reliable 
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and valid instrument for assessing psychiatric symptoms and behavioural 
disturbances in the residents of nursing homes [54].   
Spin-off versions 
The content of NPI and NPI-Nursing Home (NPI-NH) are identical but have been 
rephrased appropriately. The caregiver distress scale on the NPI has been changed to 
an occupational disruptiveness scale for the NPI-NH to allow an assessment of the 
impact of behavioural disturbances on professional caregivers. Ten- and 12-question 
versions are also available, and the latter includes night time disturbances and 
appetite as the two last items. NPI and NPI-NH scales are therefore assumed to be 
similar and comparable. The use of a subscale is also commonly endorsed by the 
neuropsychiatric domain hypothesis, but its clinical validity is questioned [110, 111]. 
It has also been discouraged by Cummings [107]. Several spin-off tests have also 
been tested, such as the quicker NPI-Questionnaire, the more elaborative NPI-
Clinicians, and the NPI-diary version that is focused on detecting temporal changes in 
nursing homes. NPI-Questionnaire is the most frequently used spin-off version.  
Criticism of the NPI 
Some psychiatric symptoms described in dementia are not included in the NPI or are 
assumed to be covered to some extent by existing items. Symptoms such as 
ruminative behaviour, repetitive and compulsive behaviour, and somatoform 
behaviour are not reported, but they are included in the NPI-Clinicians [53]. NPI is 
currently the most comprehensive tool, but hypersexuality is left out and spousal 
violence is not explicitly mentioned.    
The ease-of-use weighted against the questionnaire being too short or superficial will 
always emerge, especially for patients with excessive and severe symptoms. More 
specific and pinpointed tests such as the Cohen–Mansfield Aggression Scale and the 
Geriatric Depression Scale are often used in addition to the NPI. Cummings et al. 
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argue that they never intended the NPI to be fully comprehensive but that it was 
intended to minimise administration time [108].  
However, criticism has also been raised as to whether the NPI in combination with a 
clinical cohort may exaggerate the frequency of clinically significant NPS [112]. The 
primary validity testing was performed in the spouses of 40 non-demented elderly 
patients who showed a mean depression item score of 0.25 (range, 0–6), disinhibition 
score of 0.13 (range, 0–4), and irritability score of 0.05 (range, 0–2). Cummings et al. 
(1995) concluded that ‘NPI scale scores should be regarded as important evidence for 
the presence of psychopathology.’ No larger study on healthy elderly using the NPI 
or NPI-Questionnaire was found, but one study showed a mean NPI-Questionnaire 
total score of 0.67 (SD 1.54, n=3644) in participants who did not convert to dementia 
[113].  
The NPI is a structured interview for carers, rather than for the patients. Investigators 
continue to be concerned about the limitation of collecting data only from the 
informants because the patient’s own experience may be disregarded and there is a 
risk of reporting bias. This concern was made explicit by a consensus paper published 
by an expert panel that was convened by the Alzheimer’s Association in collaboration 
with leaders in academia and industry [114]. Although patients with mild dementia 
may have good insight into their symptoms, describing the frequency and severity is 
often difficult and requires a high degree of self-awareness and episodic memory. 
The inability to acknowledge symptoms is a key part of dementia. The NPI does not 
necessarily reflect the emotional state of patients, but rather their objective states and 
behaviour.  
The increased use of NPI and the lack of proven effective pharmacological treatments 
have raised concerns regarding the validity of NPI [52]. However, studies about 
tapering of drugs and non-pharmacological interventions have shown an effect, and 
many studies using more specific scales have shown equally poor effects of 
pharmacological interventions. Other scales include the Behavior Rating Scale for 
53 
 
Dementia of the Consortium to Establish a Registry for Alzheimer’s Disease 
(BEHAVE-AD), Brief Psychiatric Rating Scale (BPRS),  and Present Behavioural 
Examination (PBE), but these scales have not shown better dynamic validity in 
describing symptoms [25, 52-54]. 
9.3 Neuropathology 
Extent of use in the thesis  
Diagnosis of patients in article 2 is based on a definitive diagnosis in a subgroup and 
article 3 quantifies pathology related to psychotic symptoms. The neuropathological 
methods were not fully described in article 3, and they are, therefore, included as 
supplements to article 3 in the thesis.  
The final diagnostic assessment included the Braak stage of tau pathology (0–6), 
amyloid plaques CERAD (Consortium to Establish a Registry for Alzheimer Disease 
assessment) probability of AD (0-C), Braak stage of alpha synuclein pathology (0–6), 
and vascular pathologies including cerebral amyloid angiopathy (none, mild, 
moderate, severe) and small vessel disease (none, mild, moderate, severe). Vascular 
pathologies, such as amyloid angiopathy and small vessel disease were scored 
according to the Vascular Cognitive Impairment Neuropathology Guidelines [13, 27, 
37, 115]. 
9.3.2 Neuropathological diagnosis 
Each case was assessed by an experienced neuropathologist who was blinded to 
clinical data. Pathological diagnosis was made thereafter according to an international 
consensus with reference to the diagnostic criteria for AD, DLB, and PDD. Patients 
were classified as having DLB if the likelihood of a DLB syndrome was 
‘intermediate’ or ‘high,’ according to McKeith et al. [27]. The presence of possible 
co-existing TDP-43 proteinopathy was assessed according to the guidelines, and 
microscopic vascular lesions were considered and recorded.  
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Patients with borderline DLB/PDD pathology at autopsy were classified as PDD or 
DLB if they had a clinical diagnosis of PDD or DLB, respectively. The few patients 
who were misidentified as AD or DLB all had significant NPS. The pathological 
evaluation suggests that although both parkinsonism and visual hallucinations are 
common in AD, even when they occur several years after the dementia diagnosis, 
they may indicate Lewy body pathology [99]. 
9.3.3 Consideration regarding neuropathology 
The importance of post-mortem diagnostics cannot be overestimated when comparing 
the differences between diseases. Even with full clinical information and a long 
follow-up, there is a risk of misdiagnosis. Methodological strengths include that 
patients were diagnosed prospectively and consecutively underwent autopsy, and 
only age and duration differed between autopsied and non-autopsied patients [99].  
Categorisation 
Most patients were present in a few of the many possible pathological categories and, 
therefore, for statistical analyses used to investigate the pathological load, the scores 
were collapsed into binary categories, as follows: none/mild and moderate/severe 
according to stages 0–4 compared to stages 5–6 (Braak-tau and alpha-synuclein), 
CERAD class 0–B compared to class C, and cerebral amyloid angiopathy and small 
vessel disease scored as none/mild compared to moderate/severe. None of the 
collapsed categories were originally continuous scales, but ordinal categories defined 
by pathologists. Currently, efforts are being made to quantify the pathological data 
from the Demvest study, but the quantification of these data is not yet complete. The 
approach of collapsing categories reduced the risk of a type 1 error as the outlier 
contribution is reduced. Both the low number of patients and categorisation of data 
increase the risk of type 2 error and dismissing an actual association. With the small 
sample size in the current study, little importance was therefore given to the lack of 
association that was found for the severity of Lewy-body pathology or amyloid 




The presence and interactions of multiple pathologies in the brain of patients with 
dementia, as observed in this cohort, is well known [116]. Nine AD patients had 
some degree of TDP-43 pathology: two had mild pathology in the amygdala only, 
and two had mild, four had moderate, and one had severe pathology in the amygdala 
and hippocampus; one of these patients also had mild TDP-43 proteinopathy in the 
neocortex. Six DLB/PDD patients had TDP-43 pathology, five had moderate changes 
in the amygdala and hippocampus, and one had severe pathology in the amygdala and 
moderate pathology in the hippocampus and neocortex. Vascular pathology, such as 
amyloid angiopathy and small vessel disease was common in both AD and DLB/PDD 
patients, and some patients also had infarctions. Regarding vascular pathology and 
evaluating its contribution to dementia, we applied the concepts outlined in our recent 




9.4 Ethics and legality 
The Demvest study was approved by the Regional Committee for Medical and Health 
Research Ethics, Western Norway (167.04) and the Norwegian Authorities for 
Collection of Medical Data. The patients provided written informed consent to 
participate after the study procedures had been explained in detail to the patient and a 
caregiver, who was usually the spouse or son/daughter. 
All data from the Demvest study are kept in accordance to Norwegian 
recommendations on data privacy, and they were anonymised to as high a degree as 
possible. At certain points, such as obtaining data from the National Death Registry, 
the data must be re-personalised.  
With the long-term course presented in article 2, carers may assume that a certain 
course is their family member. Describing individual patients will always include a 
risk, but we tried to disguise any specific information and only provide very general 
descriptions. Thus, the risk of identifying a participant is regarded as extremely low.  
Patients received the usual treatment, or standard-of-care, or the treatment may have 
been better than usual because of the annual study assessments, compared to off-
study patients who would normally be followed by nursing home staff only. CSF 
analysis and radiological techniques may have been used to a larger extent in the 
study than in common clinical practice, but all procedures were in accordance with 
standard clinical recommendations.  
Lumbar puncture may sometimes be painful and carry a risk of adverse effects, which 
in most cases, are mild and transient. DaT-Scan imaging has some radiation risks, 
although this is minimal, and this test was only performed once. Repeated contact 
with specialised health care may cause over-diagnosis and secondary overtreatment. 
The cognitive threshold for inclusion into the study is rather high, meaning that all 
patients had only mild everyday functional deficits. Specialised health care in the last 
decade has requested restrictive use of psychopharmacology, and thus the participants 
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likely had a lower risk than non-participants of receiving a dangerous drug treatment. 
Additionally, a secondary positive effect of more focus on these patient’s care cannot 





The first article’s aim was to profile the frequency and associated variables of NPS 
over 5 years in patients with mild dementia. 
Neuropsychiatric symptoms were common at baseline, and we observed only a 
moderate increase in the average NPI total score, from 15 to 17, with no increase in 
the proportion of patients with high NPI total scores. Ninety seven percent scored 
≥16, and 49% scored ≥36 on the NPI total score at least once during follow‐up. The 
most common symptoms reported were apathy (83%), depression (63%), appetite 
(63%), and aberrant motor behaviour (60%). Cognitive decline was associated with 
higher NPI total and several NPI item scores. Only the frequency of apathy increased 
significantly over time. LBD was associated with a higher NPI total score and 
psychotic symptoms compared to AD. 
Article 2 
The second article’s aim was to describe the individual course for up to 12 years from 
the diagnosis of dementia to death in people with AD and LBD. 
Nearly all patients had NPS while 50% had a stable modest NPI total score ≥12 and 
25% had a stable NPI total score ≥24. Very severe NPS (≥48) were mostly single 
episodes, but 8% of AD patients had stable severe NPS. The AD patients with the 
highest 20% of NPI total scores had a more stable or a relapsing course for the four 
key symptoms: aberrant motor behaviour, aggression/agitation, delusions, and 
irritability. This was not seen in LBD. There were wide variations between patients, 
diagnoses, and specific NPS. Single episodes represented the most common course, 
followed by a relapsing course, while a stable course was less common. Additionally, 
57% of AD and 84% of LBD patients had reoccurring psychotic symptoms. 
Hallucinations were more frequent and stable in LBD, while aggression in more 





We investigated the post-mortem pathological correlates of severe psychotic 
symptoms.  
Neuropathologic assessments were available in 31 AD and 16 LBD patients who had 
been followed from mild dementia to death. AD patients with early and severe 
hallucinations and delusions had more severe cerebral amyloid angiopathy than those 
without psychotic symptoms. No significant associations between pathological scores 




About the discussion 
The objective of this discussion is to present and discuss the complete thesis as a 
whole, whereas discussion of the specific papers is provided in the respective articles. 
I have concentrated the findings based on both scientific and clinical perspective into 
six key points. These key points are critically discussed after an interpretation of the 
findings from the most important and similar published studies.  
Key points for discussion  
Part 1: Longitudinal course of NPS 
1. Neuropsychiatric symptoms are common in mild dementia and their increase 
is only moderate. NPS in mild dementia may therefore be under-recognised if 
it is not explicitly assessed.  
2. Over the long-term, NPS are mostly relapsing or single episodes. There are 
large individual variations that support the need for personalised medicine. 
3. Because most patients exhibit repeated psychotic symptoms, these symptoms 
should be emphasised in communications with patients and carers.  
Part 2: Differences between AD and DLB 
4. LBD patients have more NPS in mild dementia and there are more delusions 
and apathy, but NPS are also more often single episodes compared to AD..  
5. NPS are more stable in AD than LBD patients, and there is a subgroup of AD 
patients with a severe course of wandering, aggression, delusions, and 
irritability. 
 
Part 3: Neuropathological correlates of NPS 
6. Advanced cerebral amyloid angiopathy was associated with persistent and 




11.1 Findings in context 
Meta-analyses and reviews have shown large differences in the frequency and 
persistency of NPS. The results from the Demvest study (baseline and 5-year 
cumulative results) are presented together with both of the key reviews by Selbæk et 
al. and van der Linde et al. in Figure 5. The Demvest study fits well within the large 
variation described in these studies. The 5-year cumulative frequency (six 
assessments) of NPS is higher in the Demvest study than in the reviews, but very few 
studies have more than 3–4 assessments.   
The frequency and persistency of key studies with a similar prospective longitudinal 
design and inclusion criteria are presented in Figure 6. Because of the variation in 




Figure 5. The frequency (top, in %) and persistency (below, in %) of different NPS in 
the reviews and in the Demvest study. Not all studies provided information on all 




Figure 6. The frequency (top, in %) and persistency (below, in %) of different NPS in 
key studies presented in text and the Demvest study using NPI. Not all studies 
reported the persistency [1, 59, 84, 102, 117]. 
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11.1.1 Key studies compared to the Demvest study 
Cache County study 
The large prospective population-based ‘Cache County study’ was a dementia 
progression study that followed patients for 5 years and reported the prevalence, 
persistency, and trajectory of NPS [48, 70, 101, 117-119]. With initial screening of 
5677 patients, 437 dementia patients were identified, among whom 236 had at least 
one follow-up. This is one of the largest longitudinal studies of NPS in dementia. 
However, because of a high drop-out rate, only 36 patients had four follow-ups (5.3 
years). With the number of patients, the long-term follow-up and the wide range of 
NPS assessed, this is the closest study compared to the Demvest study. The Cache 
County study showed that the risk of any NPS was 56% at baseline and the 
cumulative incidence was 95% [117]. The same symptoms were most frequent 
(depression, apathy, and anxiety), and thus, the findings were comparable to the 
Demvest study. The Demvest study had a higher 5-year cumulative prevalence 
probably because of a higher number of repeated assessments. More extroverted 
symptoms such as hallucination, aggression, disinhibition, and aberrant motor 
symptoms were more frequent and more severe in the Demvest cohort. The higher 
rate of these symptoms may be because of the more progressed dementia stage in the 
Cache County study. A mean MMSE of 14 was reported in a persistency analysis 
(n=117) [120], while the 5-year prevalence analysis did not provide MMSE, but 15% 
had a CDR core of >2 already at baseline (n=236) [117]. This is an important 
difference compared to the Demvest study, which had a mean MMSE of 24 and 
excluded patients with CDR ≥1. The Cache County study also had a higher attrition 
rate in patients with hallucinations, aggression, disinhibition, irritability, or aberrant 
motor behaviour than in those without these symptoms [117]. As will be discussed 





The LASER-AD study from England followed only AD patients (n=198) and 
reported the frequency of all 12 NPI items at baseline and after 6 months of follow-up 
[102, 121].  Although shorter than the Demvest study, the LASER-AD study provides 
good diagnostics and an epidemiologically representative sample of mild, moderate, 
and severe AD patients. Thirty-three percent of the patients were in nursing homes 
and the remainder were home-dwelling. LASER-AD found that patients with any 
NPS were very common (75%) and highly persistent over 6 months (96%), and the 
NPI total score was not associated with living at home or in a nursing home. They 
reported a similarly high frequency and persistency similar to the Demvest study, 
although the LASER-AD study reported a lower frequency and persistency of 
hallucinations in their AD patients than in the overall Demvest group. This was 
probably because of the DLB patients in the Demvest study. In our AD subgroup, we 
report a 5-year frequency of hallucination of 40% compared to a 19% baseline 
frequency in the LASER-AD study (NPI ≥1). A lower persistency of NPI was present 
(item score >0) compared to clinically significant NPS (score >3), which was similar 
to the Demvest study. LASER-AD found no association between psychotropic drug 
use, use of services, cost of care, and improvements in NPS, while the MMSE decline 
was the only significant predictor of increased NPI score. Their focus is the low 
effect of proposed treatment measures. The authors propose that a shorter follow-up 
and selectively including AD distinguishes their study from other studies. Compared 
to Demvest, the structured inclusion of dementia stages could also induce bias 
because several NPS are associated with a lower MMSE score that is intermittent or 
stable [102]. Both LASER-AD and Demvest are clinical cohorts that were recruited 
through health care worker referrals, and they have a risk of selection bias. LASER-
AD also showed that aggression accounted for 12% of the health and social care costs 





The MAASBED study from The Netherlands reported data from 99 patients (among 
the 199 patients who were included) for 2 years, with 6-month assessment intervals 
[59]. Patients were recruited from specialised health care but living at home. Among 
those who were initially included, 75% were diagnosed with AD, 16% with vascular 
dementia, and only 4% with DLB. Diagnoses were not included in the analysis but 
were reported as all-cause dementia. The mean MMSE was 18 with a decline of 1.7 
points per year, which is consistent with the Demvest study (mean, 2.1), considering 
both the higher frequency of DLB and the floor-effect of MMSE. The frequency of 
NPS was similar, except for more hallucinations and night time behaviour symptoms 
in the Demvest group, and both of these symptoms are frequent in DLB.  
The persistency reported for 6, 12, 18, and 24 months in the MAASBED study was 
lower than in the Demvest and LASER-AD studies (Figure 6). Apathy was still the 
most persistent but there were large differences. For example, there may be a 
difference in the clinical management of delusion if the persistency is 11% 
(MAASBED) or 53% (LASER-AD) compared to 50% (Demvest). The reason for 
lower persistency of symptoms in MAASBED is not clear, but the persistency on any 
NPS (defined by NPI total >3) was 65%. These data are consistent with the Demvest 
results, in which 78% had a stable course with NPI total ≥1, and 46% had a stable 
course with NPI total ≥12 (Article [2]). The MAASBED authors suggest that the risk 
of selective attrition biased the results, and they also argue the importance of using 
sub-syndromes (see the data reduction below).  
In the MAASBED study there was no increase of the NPI total score over 2 years, but 
there was an increase in apathy and aberrant motor behaviour analysed and a decrease 
in depression assessed by the mean item score. A statistical model without cognitive 
decline showed that time was significantly associated with this increase. The 
Demvest study showed no change in depression, but there was an increase in the 
frequency of clinically significant symptoms of apathy and aberrant motor behaviour, 




In a 3-year follow-up study from Australia (Prospective Research in Memory clinics, 
the PRIME study), Brodaty et al. enrolled 511 patients, with 331 patients completing 
the study, and these patients were assessed on six occasions using the NPI [84]. 
Patients were recruited from specialised memory clinics. Only patients living at home 
were included in the results. With a MMSE of 22% and 85% and a CDR score of 0.5 
or 1, this is the closest cohort to the Demvest study in terms of dementia stage. 
Patients were diagnosed based on clinical criteria, and 67% of patients had AD, 15% 
of patients had vascular, and only 3% of patients had DLB. Baseline severity of 
dementia was associated with a higher NPI total score. The severity of symptoms 
including delusions, hallucinations agitation, anxiety, apathy, and aberrant motor 
symptoms was associated with time, while the cognitive decline was not modelled in 
this study. Demvest study showed similar effects of time, but this effect was not 
significant when the MMSE decline was introduced into the model in article 1. A 
similar sex difference as in the Demvest study was reported with higher risk for 
apathy in men and anxiety in women, and Demvest study found that women were 
also more likely to have delusions. Besides the differences in LBD frequency, the key 
outcome variable was analysed quite differently. Both the MAASBED study and the 
PRIME study used mean the NPI score, which required transformation of the data 
before analyses because of the skewness. Although statistically handled, this 
introduces the question of whether the NPI scores should be treated as a continuous 
or ordinal (non-continuous) scale. The Demvest study is presented and analysed using 
the clinical cut off NPI ≥4 [1]. 
The main conclusion of the PRIME study is that NPS worsens over time, and that 
symptoms have different trajectories associated with sex, diagnosis, and the use of 




The Hope et al. study is unique because it is an up to 10-year follow-up study with 4-
month assessment intervals as part of the Oxford Project to Investigate Memory and 
Ageing (OPTIMA) [58, 122, 123]. OPTIMA was a collaboration between post-
mortem examinations and computed tomography scans. The study sample was 
initially 100 patients, of whom 48 had pathologically confirmed AD and most results 
were based on this group. There was low attrition for causes other than death. The 
mean follow-up time was 3.3 years and the focus of the study was also the course of 
behavioural symptoms.  
OPTIMA did not use NPI, but Present Behavioural Examination (PBE) and thus, 
comparing results directly is difficult. The PBE rates most items on a seven-point 
frequency scale (0–6), depending on the proportion of days on which the behaviour 
occurred. PBE also took into account carer-reported behaviour within the last 4 
weeks. Hope et al. rated an episode if it was ‘persistent and severe’ which does not 
include an isolated episode (PBE score 1). This is similar or more restrictive 
compared to NPI and our clinically significant cut off (NPI ≥4) because we did not 
include any symptom that occurred less than once per week. Although key symptoms 
are likely to be similar, delusions were compared to persecutory ideas (46%) and 
hallucinations were considered to be auditory hallucinations (26%), while in the 
Demvest study, the 5-year cumulative frequency was 41% and 24%, respectively. 
With a mean follow-up time of 3.3 years in Hope et al., the frequencies are best 
compared to the Demvest study 5-year frequency, and not to the full course cohort 
that has a mean follow-up time of 6.4 (SD 2.9) years. A 4-month assessment interval 
in the OPTIMA study did not seem to increase the cumulative frequency compared to 
the 1-year assessment interval in the Demvest study, although the differences 
described should be interpreted with caution.  
The OPTIMA study reported that all patients with dementia had NPS to some degree 
during a long-term follow-up, and the course of the symptoms was different. Most 
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patients had persistent symptoms until death or single episodes. A relapsing–
remitting pattern was less common. Fewer than 14% of people who were rated 
positively for a symptom had more than a single episode. They also argued that the 
data supported the view that behavioural and psychiatric changes occur 
predominantly at a late stage of the dementing illness. It is difficult to compare the 
OPTIMA and Demvest studies because of the differences in design and instruments 
used, but many AD patients with persistent severe NPS is a common finding in both 
studies. Hope et al. conclude by stating the importance of NPS instability in trial and 
management evaluation, which is the similar to the conclusion raised by the Demvest 
study [58].  
ADNI 
A more recent study presented the course of NPI total scores in an AD cohort 
(n=181) that was initially designed to evaluate if positron emission tomography 
(PET), other biological markers, and clinical and neuropsychological assessments can 
be combined to measure the progression of mild cognitive impairment and early AD 
[61]. The mean MMSE score was 23, and patients were assessed using the NPI-
Questionnaire at baseline and at 6 months, and they were grouped into persistent 
(both assessments), fluctuating (one assessment), and no NPS based on the NPI total 
score ≥4. AD subjects with persistent and fluctuating NPS showed more atrophy of 
the right and left prefrontal cortex compared to those with minimal/absent NPS. AD 
subjects with persistent or fluctuating NPS showed worse cognitive and functional 
outcomes compared to AD subjects with minimal/absent NPS. Although only 
including a 6-month time-span, this study showed a biological difference in patients 
with more stable NPS either as cause or consequence of NPS. The cohort with mild 
dementia is similar to that of the Demvest study and the proportion of patients with a 




EADC and data reduction  
Several large cross-sectional studies argue that NPS are clustered together in sub-
syndromes such as psychotic and affective syndromes. The NPI was not originally 
designed for this [108]. However, several studies show the data in domains that were 
acquired statistically or logically. One such key study is the meta-analysis from the 
multicentre European Alzheimer’s Disease consortium (EADC) collection of 2,354 
patients with ‘any dementia’ [62, 124]. The EADC data showed convincingly that 
NPI in cross-sectional data can be reduced to domains such as psychosis, 
hyperactivity, and affective using principal component analysis. They also reported 
that the diagnosis was a less important predictor of NPS (see the discussion below). 
Longitudinal data have challenged the usefulness of such domains [110, 111], and the 
theoretical background regarding both the assumption of the NPI item scores as 
continuous and the data inflation of scores equal to 0. The data from the PRIME 
study on NPS were analysed according to NPS domains hypothesis, showing a lack 
of stability in the domains at the group level [111]. This thesis has therefore explicitly 
avoided data reduction methods.  
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11.2 Longitudinal course of NPS 
 1. Neuropsychiatric symptoms are common in mild dementia and their 
increase is only moderate. NPS in mild dementia may therefore be under-
recognised if it is not explicitly assessed. 
Key reviews and text books report an increase in NPS over time and increasing 
dementia severity based on cross-sectional data that is transformed into a longitudinal 
course that shows an increase in NPS according to severity or a crescendo-
decrescendo effect, with the highest NPS scores in the moderate-to-severe group [23, 
52, 55-57, 62, 125]. These cross-sectional studies have more selection bias, with the 
risk of patients being recruited into studies and more recall bias as patients and carers 
are seeking help. Most longer-term studies are nursing home studies that often have 
multi-morbid and severely demented patients [57, 62]. Therefore, truly long-term 
cohorts with low attrition rates and proper diagnostics that are relevant to current 
clinical practice are a priority [52, 55]. The Demvest study provides such a cohort. 
The observed small increase in the mean NPI total from 15 to 17 over 5 years is 
unlikely to be clinically significant. Other studies such as PRIME, LASER-AD, and 
Cache County show the same statistically significant increases, but also the same 
very modest increase with no increase in mean NPI item score more than 1 point and 
no NPI total score more than 3 points. The NPS in mild cognitive impairment (MCI 
are under investigation in many studies after the minimal behavioural impairment 
initiative, and NPS are reported to be common at the MCI stage [25, 50]. The Cache 
County study also found a high risk for NPI in patients with cognitive impairment 
and no dementia, and a higher risk of conversion to dementia in people with NPS 
[119].  
There is an important distinction between time and cognitive decline, although 
dementia progression is assumed to be inevitable. The association between NPS and 
the cognitive decline is probably not causative, and they may affect each other and 
other unknown factors may affect both these factors. NPS may impact the cognitive 
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decline in several ways, but the most discussed is the permanent negative effects on 
elderly brain plasticity.  
The large differences between studies do not seem to have any geographical or 
sociological causes [56], but are most likely a result of the recruitment and 
assessment differences. Because many symptoms are both phenomenologically hard 
to describe and stigmatising, and they place patients at high risk of unwanted 
consequences (e.g. patient–carer disputes or institutionalisation), a structured 
interview is appropriate.  
 
2. Over the long-term, NPS are mostly relapsing or single episodes. There 
are large individual variations that support the need for personalised 
medicine. 
Longitudinal studies with high follow-up rates and structured assessments such as 
LASER-AD, MAASBED, and PRIME are all in agreement with the van der Linde et 
al. meta-analysis but the description is limited to group levels and there is a high 
degree of variability. Using these data for clinical management is difficult and further 
studies are required. In article 1, we show a high rate of symptom reoccurrence (57–
86%), and in article 2, there are large variations between patients. Most patients have 
an intermediate overall score with many single episodes or relapsing individual 
symptoms. Some patients had complete symptom resolution late in the disease 
course, even those patients with severe symptom scores. The pattern of relapsing or a 
single episode course was more pronounced among patients with higher item scores. 
Apathy was the most stable symptom in both AD and LBD, with 34% and 27% of 
patients having stable apathy, respectively.  
Hope et al. argue the difficulty of assessing the intervention effects and this issue is 
raised by several others [52, 58]. The lack of intervention efficacy is often suspected 
based on mostly negative clinical trials, but the design of such studies must take into 
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account the unstable symptom course. Non-pharmacological interventions could be 
less sensitive to these variations because they are unblinded and person-specific. A 
large generalised clinical effect of any of our current medications are less likely.  
A diagram of AD patient movements between NPI total severity levels from baseline 
to the fourth follow-up is provided to illustrate the complex longitudinal course 
(Figure 7). Except for a small group of patients with very significant NPS, there was 
a high degree of instability.  
 
 
Figure 7: A Sankey diagram of the NPI total scores according to severity level, 
showing the stability from baseline to the fourth follow-up (4 years). Insign, 
Insignificant NPI total 0–11 (including both Present (<11) and None); Modest, NPI 
total 12–23; Significant, NPI total 24–47; and Very Significant, NPI total 48 or more. 
The order of categories within each follow-up is based on the closest relationship.  
Baseline          Year 1             Year 2          Year 3               Year 4 
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3. Because most patients exhibit repeated psychotic symptoms, these 
symptoms should be emphasised in communications with patients and 
carers.  
 
Psychotic symptoms carry with them direct consequences of agony, burden, and loss 
of self-preservation, but also many indirect consequences such as institutionalisation 
and isolation. The current management assumes that psychotic symptoms are 
common and most often are permanent. We show that 94% of LBD and 77% of AD 
patients experienced at least one psychotic symptom (NPI ≥1 for delusions or 
hallucinations). In LBD, 83% had reoccurring psychotic symptoms, compared to 57% 
of AD patients, while clinically significant hallucinations (NPI≥4) had a stable course 
in 24% of LBD and only 4% of AD patients [2]. The findings in the Cache County 
study are the closest to our findings, while other shorter studies with fewer follow-up 
assessments found lower frequencies (Figure 6). The Demvest study 5-year psychosis 
frequency was similar to the OPTIMA study that also followed a long-term course. 
Even with potential bias of more psychiatric recruitment in the Demvest cohort, the 
data are consistent with the common occurrence of psychotic symptoms in dementia, 
and the unstable course in most of these patients. These changes in clinical 
understanding are important because they can improve management through an 
increasing effort to identify and understand psychosis as an integral part of dementia. 
A shift in the focus from permanent to episodic symptoms may increase efforts from 
carers to stimulate and continue their activities of daily life. For scientific studies, 
these data show the need for longitudinal assessment of NPS when identifying a 




11.3 Differences between AD and LBD 
4. LBD patients have more NPS in mild dementia and there are more 
delusions and apathy, but NPS are also more often single episodes compared 
to AD. 
 
All three articles reveal significant differences in NPS between AD and LBD, which 
is in contrast to studies, meta-analyses, and a review that conclude that NPS are 
similar between these diagnoses, which justifies reporting of all-cause dementia.  The 
largest meta-analysis study from European Alzheimer’s Disease consortium (the 
EADC) found no differences in NPS between different diagnoses [62]. The Cache 
study reported that there were no differences in the prevalence of neuropsychiatric 
symptoms between participants with Alzheimer-type dementia and those with other 
dementias combined, with the exception of aberrant motor behaviour, which was 
more frequent in Alzheimer-type dementia [126]. However, we found differences in 
both hallucination and night time disturbances, both of which are core symptoms of 
LBD [27, 64, 84]. The Demvest study provides findings that are complementary with 
other studies that describe differences in core clinical symptoms of DLB and AD, but 
this study also showed that these differences in symptoms decrease with increasing 
dementia severity. This observation is consistent with the total load pathology 
hypothesis and the consequence is a risk of misdiagnosis in patients with late onset 
core DLB symptoms [99]. 
The Demvest study shows a higher frequency of both apathy and delusions in LBD. 
Depressive symptoms were higher on the Montgomery and Åsbergs Depression 
Rating Scale (MADRS) score at baseline, and a higher apathy score was shown on 
the NPI in LBD patients in the early phase of the disease [1, 127]. In the Demvest 
study, apathy was more extensively studied and found to be associated with a faster 
global cognitive decline and early nursing home admission in DLB [128]. These 
findings are consistent with studies with a high diagnostic accuracy and that focus on 
mild dementia using the DSM‐IV diagnosis showing the largest difference in 
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symptoms such as anhedonia and fatigue compared to AD [65]. Other studies may 
have missed this effect if it was most evident in mild-to-moderate dementia patients 
and it has never been shown in previous long-term longitudinal studies.  
Although much focus is on hallucinations, delusions were also reported as a common 
symptom in LBD and also recently in prodromal LBD [129]. The Demvest study 
reports both a higher frequency of delusions that are associated with a cognitive 
decline, and a more unstable course of delusions compared to AD. Delusions are 
associated with an overall severe NPS trajectory in all-cause dementia. It has 
previously been shown that DLB patients who presented with delusions had poorer 
cognitive function, but few studies have followed patients longitudinally. Ballard et 
al. reported no difference between AD and DLB in the frequency or severity of 
delusions over 6 months in mild dementia patients living at home [130]. None of the 
other large studies reported differences in delusions [84, 117].  
The lower sensitivity of MMSE to detect DLB (because it was designed for AD) and 
the shorter survival time may indicate that the Demvest study had biased recruitment 
of more severe LBD patients compared to AD patients. However, there was no 
difference in the CDR score at baseline, but there was a significantly more rapid 
decline in DLB patients [105]. In contrast to MMSE, the CDR captures the full range 
of functional deficits resulting from cognition, as judged by a trained clinician after 
interviewing the patients and caregivers, and it is likely a more accurate and 
comprehensive measure of severity. However, the CDR was also developed for use in 
AD and has not been adequately tested in DLB. In the articles from this thesis, LBD 
includes Parkinson’s disease dementia (PDD). A recent study with a focus on PDD 
compared to DLB showed that PDD patients had fewer delusions and had an NPS 
profile that was similar to AD [131].  
Differences in NPS between AD and LBD are important because they could describe 
a different biological underpinning. If LBD apathy and depression are closer to 
Parkinson’s disease, there might be better intervention strategies related to 
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hypodopaminergic states such as piribedil for apathy and pivamanserin for psychosis 
[132, 133].  
 
5. NPS are more stable in AD than LBD patients, and there is a 
subgroup of AD patients with a severe course of wandering, aggression, 
delusions, and irritability 
A long-term assessed subgroup with severe and psychotic symptoms in articles 2 and 
3 is novel, although AD is associated with more severe NPS. The Demvest study 
provides a large number of patients, long-term follow-up, and, importantly, a 
definitive diagnosis in a high percentage of patients. Our analysis of diagnostic 
accuracy also describes that patients with severe NPS are especially complex and 
difficult to accurately diagnose clinically [99]. The ADNI study identified a group of 
subjects with persistent NPS over only 6 months, with atrophy of the right and left 
prefrontal cortex in AD compared to others. The ADNI study also provided rigorous 
diagnostics.  
We did a sub-analysis in our data in article 3, which showed a loss of difference 
between groups when using the last assessment and ever present psychotic symptoms 
compared to severe and persistent symptoms. The last assessment and ever present 
symptoms are two common ways of analysing psychosis data [83, 86]. However, our 
negative finding cannot be strongly weighted because of the lack of power with a 
small sample size and the risk of type II error. 
An increased effort to identify AD patients with persistent and severe NPS may 
improve ordinary treatment and treatment in a clinical trial. This group may represent 
the outliers and an important clinical and biological subgroup [86]. Although 
aggression has been targeted in studies, no novel treatment has emerged. It can be 
speculated that they represent a group with inconsistent treatment plans based on an 
emergency, a high degree of polypharmacy, and re-occurring hospital admissions. 
This group of patients may be especially hard to study, because they are only a small 
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group, they do not fit standardised trial inclusion criteria, and they can seldom 
provide consent. Early identification through NPS and imaging may have the 
potential to improve clinical trials. 
11.4 Neuropathological correlates of NPS 
6. Advanced cerebral amyloid angiopathy was associated with persistent 
and severe psychotic symptoms in AD  
Cerebrovascular pathology such as small vessel disease has been associated with 
depression in elderly people, but few studies have addressed psychotic symptoms. In 
a large neuropathological AD study (n=1618), vascular pathology was not found to 
be associated with psychosis ever present, but subcortical arteriosclerotic 
leukoencephalopathy and vascular risk factors were associated with this symptom 
[91]. Vascular risk factors did not predict a change in NPS in the Cache County 
study, but the use of antihypertensive medications was associated with a higher NPI 
total score and affective symptoms, but not psychosis [101].  
Our sample had considerable co-morbid vascular pathology, but the patients were 
diagnosed clinically and pathologically with AD, and our findings are consistent with 
others regarding the high CAA presence [16, 134]. It is not likely that misdiagnosis of 
primary vascular pathology biased the results because prevalence of post-stroke 
psychosis is also much lower than in AD and DLB [135]. As one of a few prospective 
longitudinal studies, OPTIMA also assessed neuropathology, but NPS associations 
with neuropathology have not been published. OPTIMA found a relationship between 
CAA and subcortical tissue damage, and they concluded that vascular disease had a 
modest contribution to cognitive impairment in AD [136]. These results were 
consistent with more recent publications showing the low impact of vascular damage 
on the progression of AD [39].  
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Causative conclusions cannot be drawn from post-mortem studies because of the 
cross-sectional and end-stage pathological data. Cerebrovascular pathology may take 
many years to develop and is associated with the duration of life and genetic risk 
factors [35, 115].   
Both genetic, clinical and pathological studies show how immune reactions and 
vascular pathology are important in psychosis development [16, 137]. Systemic 
inflammation is also known to play a key role in small vessel disease and to induce 
CAA through the blood-brain barrier pathway [138-141]. Inflammation may be a 
possible link between vascular pathology and psychosis in dementia. Monitoring and 





NPS should be highlighted as an important part of the dementia syndrome even in 
mild dementia. Although apathy and affective symptoms are most common, 
aggression, irritability, and wandering should be emphasised to the general public as 
integral aspects of the disease. Psychotic symptoms, which carry strong prejudice and 
stigmata, should be screened for and integrated as a part of dementia patient treatment 
and management.   
 
Health care level 
Focus on the high frequency and relapsing remitting course of severe NPS can 
improve patient care and management. If patients are provided with strengthened 
home-based support or short-term nursing home placement with a focus on 
maintaining daily life-function, the consequences of single NPS episodes could be 
reduced. Identification of those patients a with good prognosis may be just as 
important as identifying those with a poor prognosis. A proper diagnosis is essential 
in managing NPS.  
 
Research 
An unstable course of NPS when assessing all-cause and all-level dementia must be 
taken into account when designing and interpreting trials. The importance of a correct 
diagnosis, especially in patients with psychotic symptoms, should also be noted. 
81 
 
13. Future perspective 
The rigorous diagnostic procedures and long-term follow-up period of NPS in the 
Demvest study reveal more information about the relationship of NPS with the 
within-patient variation of cognitive decline and with key mechanisms such as 
vascular and inflammation and their risk factors. Identification of a high-risk AD 
group for severe NPS and a better description of the pathological mechanisms are the 
basis for a proposed future clinical trial in collaboration with King’s College, 
London. 
Identifying the role of NPS in the prodromal phase of dementia is another 
consequence stemming from the current work, highlighting that NPS are already 
prominent at the time of diagnosis. This research is being continued in a prospective 
new long-term follow-up study (Dementia Disease Initiation), focusing on people at 
pre-dementia stages, which is also underway in a multi-centre Norwegian 
collaboration.  
This work highlights the complex task of translating the knowledge about NPS into 
clinically relevant and comprehensible information. Dissemination of facts about 
NPS is of the greatest importance; enabling those with the best knowledge about the 
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Objective: Neuropsychiatric symptoms (NPS) in dementia are frequent and chal-
lenging for patients, carers, and the health care system, but few long‐term studies
exist. We analyse the longitudinal course of NPS in patients with mild dementia.
Methods: A longitudinal cohort study of 223 patients with mild dementia and
annual assessments using the Neuropsychiatric Inventory (NPI) for 5 years.
Results: A total 1043 NPI assessments, representing 97% of all possible measure-
ments of living cohort members, were analysed. Neuropsychiatric symptoms were
common at baseline, and only a moderate increase in total NPS score from 15 to 17
with no increase in the proportion with high NPI total scores. Ninety seven percent
scored ≥16, and 49% scored ≥36 on NPI total score at least once during follow‐up.
Individual NPS fluctuated and often reappeared. The most common symptoms ever
reported was apathy (83%), depression (63%), appetite (63%), and aberrant motor
behavior (60%). Cognitive decline was associated with higher NPI total score and sev-
eral NPI items, but only the frequency of apathy increased significantly with time.
Lewy body dementia was associated with higher NPI total score and psychotic symp-
toms. Alzheimer's disease was associated with increase in apathy.
Conclusions: Severe NPS are already common at time of dementia diagnosis, and
the increase in overall severity over 5 years was moderate. Individual symptoms tend
to fluctuate over time within patients and correspond to states rather than traits.
These findings highlight the need to focus on, and plan for, NPS as part of dementia
pathway, and are relevant for clinical trial design.
KEYWORDS
Alzheimer's disease, behavioral disturbances, dementia, depression: apathy, Lewy body dementia,
longitudinal, Neuropsychiatric Inventory, neuropsychiatric symptoms, psychosis
1 | INTRODUCTION
Neuropsychiatric symptoms (NPS) are common and impactful features
of dementia with key implications for patients' quality of life, carer
burden, and societal costs.1,2 Most studies of NPS (or behavioral and
psychological disturbances in dementia) are cross‐sectional, and the
few longitudinal studies have mostly been performed in nursing home
patients. Very few studies have explored the longitudinal course of
NPS in patients with dementia from the time of diagnosis. Under-
standing the full course of NPS is important to inform patients and
relatives about prognosis, to inform treatment decisions, and to opti-
mize clinical trial designs and for health care planners. The Cache
County study showed increase of NPS over 5 years but was limited
by high attrition rate with less than 10% of patients participating after
5 years.3 Another recent study4 reported increased NPS during
36 months of follow‐up; however, patients were excluded when insti-
tutionalized. Importantly, although the frequency and profile of NPS
differ between dementia subtypes, most studies report NPS frequen-
cies in all‐cause dementia rather than in specific diagnoses.3,5 Previ-
ously, we have published baseline frequency of NPS in Dementia
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DOI: 10.1002/gps.4933
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Study of Western Norway (Demvest), a cohort study of patients with
mild dementia.6 We here present the first reports of the NPS profile
and frequency during 5 years in patients with mild dementia from time
of diagnosis, reporting NPS in patients with Alzheimer's disease (AD)
and Lewy body dementia (LBD) separately.
2 | METHODS
2.1 | Study design
The Dementia Study of Western Norway (Demvest) is a longitudinal
cohort study with annual assessments of patients referred to demen-
tia clinics in Hordaland and Rogaland counties. There are no other hos-
pitals and none, or little, private health care for these patients. As
previously described,7 to reduce referral bias, the GPs in the area were
contacted by letter prior to study start and invited to refer all patients
with suspect dementia. All dementia diagnostic units (geriatric, neurol-
ogy, and psychiatric) in the region recruited to the study and all resi-
dents are covered by the same National Insurance Scheme with
restricted copayments allowing the representation of a general
dementia population. After the main inclusion period between 2005
and 2007 (“mild dementia cohort” (MDC)), we continued to selectively
recruit patients with LBD, ie, dementia with Lewy bodies and
Parkinson's disease dementia to enhance the number of patients in
this group. After screening 657 patients (Figure 1), 223 were included
in the baseline consisting of 116 ADs, 87 LBDs, and 20 other demen-
tia diagnosis (9 vascular dementia, 3 mixed AD and vascular, 5
frontotemporal dementia, and 3 alcohol‐related dementia). We
describe NPS in the MDC (n = 188), which represents a nonbiased ref-
erence cohort not including the additional LBD patients. The LBD
cohort consisted of 69 probable and 2 possible dementia with Lewy
bodies; we also included 16 Parkinson's disease dementia as there
are no major differences between these diseases in long‐term fol-
low‐up.8 Alzheimer's disease cohort consisted of 102 probable and
14 possible AD patients.
2.2 | Inclusion criteria and follow‐up assessments
Physical, neurological, and psychiatric examinations were performed,
including a detailed neuropsychological test battery, Montgomery‐
Aasberg depression rating scale (MADRS) routine blood and CSF
analyses, and brain MRI. Dopamine transporter SPECT scans were
available for most patients with suspected dementia with Lewy bod-
ies. Caregivers completed the Informant Questionnaire on Cognitive
Decline in the Elderly (the IQCODE), a questionnaire shown to be a
reliable and valid instrument to detect dementia, and the clinician
completed the Clinician Dementia Rating (CDR) scale and the
Hachinski Ischemia Scale.9-11 Patients were defined as with dementia
according to ICD 10,12 and patients with Mini Mental Status Exami-
nation (MMSE) score of at least 20 or a CDR global score = 1 were
included to represent a MDC. Exclusion criteria were no dementia or
moderate or severe dementia, acute delirium, previous bipolar disor-
der or psychotic disorder, terminal illness, or recently diagnosed
major somatic illness which according to the clinician would signifi-
cantly impact on cognition, function, or study participation. The final
clinical diagnosis was made according to the consensus criteria for
dementia with LBD, PDD, and AD (NINDS‐ADRDA) after a consen-
sus meeting with 3 specialists including both geriatric psychiatry
and geriatric medicine.13-15 A pathological diagnosis was available
for 56 patients in the Demvest cohort, showing diagnostic accuracy
above 80% for both AD and LBD.16 Patients were followed as out-
patients with annual structured assessments including Neuropsychi-
atric Inventory (NPI) and MMSE. Pharmacological and
nonpharmacological interventions followed national guidelines. Data
are included only for the first 5 years of the study period because
of reduced survival beyond 5 years. Complete medication data were
only available at first follow‐up. The diagnostic assessment is
described in detail elsewhere.7
The vast majority of dropout was because of death (Figure 1), and
only 12 patients were not examined during the year prior to death; of
these, 9 reported other serious somatic illness (heart failure, cancer), 2
long travel time, and 1 for unknown reason. The number of patients
who missed a single follow‐up assessment was 3, 4, 3, 1, and 1 for
each of the 5 follow‐up assessments, respectively, leaving a highly
representative sample with a total of 1043 NPI assessments (97% of
all possible measurements).
2.3 | Assessment of neuropsychiatric symptoms
The validated Norwegian 12‐question Neuropsychiatric Inventory was
used to interview the family or caregivers.17,18 The 12 items were reg-
istered as present and, if present, scored according to their frequency
(1‐4) and severity (1‐3), and we report the frequency × severity score
for the individual items representing the last 4 weeks. Neuropsychiat-
ric Inventory items score is a product term of 2 ordinal scales with
many of the NPI item scored as 0 (reflecting “not present”), along with
a non‐Gaussian distribution of the item score with an absence of the
numbers 5, 7, 10, and 11. This resulting scale follows a nonparametric
distribution. We used established cut‐off item score of ≥4 as a point
of determination of clinical significance, which includes a moderately
severe symptoms at frequency rating of “often” or more frequently
and “mild symptoms” present “very frequent,” as previously
reported.4,19 Neuropsychiatric Inventory total score is summed to a
maximum possible of 144, and we used NPI total score >36 as cut‐
off as suggested by others.20,21
Key points
• Severe NPS were common already early in dementia.
• NPS were present in all patients with dementia, and
severe NPS occurred in half of them.
• NPS were fluctuant, suggesting that NPS represent
states rather than traits.
• Alzheimer's disease and Lewy body dementia differed in
frequency and progression of NPS.
1362 VIK‐MO ET AL.
2.4 | Statistics
Baseline characteristics of the cohort are presented as proportions,
mean, or median values. Univariate comparisons of groups were made
with Mann‐Whitney U tests, Pearson chi‐square tests, and Student's t‐
test, the latter in accordance with the results of the Welch test for var-
iance. Because of the highly non‐normal distributions of the NPI item
scores with both considerable skew and zero inflation, the descriptive
statistics are presented as present (item score ≥1), clinically significant
(item score ≥4) and medians.
For each NPI item, we present the percentage of patients with
score ≥1 (Digital supplement, DS 2 (found in the Supporting Informa-
tion)) and ≥4 (Figure 2 and DS 2), as NPI item frequency. Item descrip-
tive values from MDC are shown in Table 3 with risk of patient ever
reporting symptom (item score ≥1 or ≥4 at any assessment). As an indi-
cator of the stability of each item on an individual patient level, we cal-
culated 12‐month persistency (percentage of patients with items also
present at next follow‐up5) and reoccurrence (percentage of patients
with reoccurring items, ie, item present at ≥2 follow‐ups). These data
are presented crude as recommended,5,22 not adjusted for missingness
or mortality.
For multivariate analysis, the NPI items were collapsed to binary
(NPI items ≥4, details DS 1 (found in the Supporting Information)) or
ordered categories (NPI‐total, details in Table 2) prior to being entered
as dependent variables for analysis in mixed effects models. A random
intercept or random intercept‐random slope model was fitted, in
accordance with the Bayesian information criterion, which was also
used to select the optimal covariance matrix. Age, gender, time, and
diagnosis (AD versus LBD) were included as fixed covariates, while
MMSE, transformed to normality by the square roots of its errors
(30 − MMSE), was included as a time‐changing covariate, measured
at each occasion allowing for odds ratio (OR) estimation. All statistical
analyses were performed using SPSS version 23 (IBM SPSS Statistics
for Windows, version 23.0, Armonk, NY: IBM Corp.) and Stata 15
(StataCorp. 2017, Stata Statistical Software: Release 15, College Sta-
tion, TX: StataCorp LLC).
2.5 | Ethical issues
The study was approved by the regional ethics committee
(2010/633) and the Norwegian authorities for collection of medical
data and received financial support from the regional health
authorities of western Norway, Helse Vest. All data were handled
and kept in accordance with national health and data privacy
protocol.
FIGURE 1 Flow chart of study design and
data retrieval
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3 | RESULTS
Cohort characteristics are shown in Table 1. The LBD and AD groups
did not differ regarding age and baseline MMSE score, but there were
more females in the AD group, while LBD had longer disease duration.
As previously described,23 the mean decline on MMSE was 2.1 points/
year, from 23.8 at baseline to 13.3 at year 5, and at the fifth follow‐up
105 of the 223 patients had died (Figure 1). At baseline, only 1 patient
(with frontotemporal dementia) resided in a nursing home, while 65%
of the participants resided in nursing homes at year 5. At first follow‐
up, 61% used antidementia drugs, 9% used antipsychotic, and 40%
used antidepressants.
3.1 | Mild dementia cohort
3.1.1 | NPI total
The median NPI total score overall increased marginally from 15 at base-
line to 17 at year 5 (Figure 2). Using a mixed effects model proportional
odds model, we found that time had a significant effect on NPI total (OR
1.70, P < .001, Table 2). When adjusted cognitive decline (OR 1.47,
P < .001) in model 2, the effect of time disappeared. The frequency NPI
total score ≥36 was stable at 20% during the 5 years. The proportion of
patients with ≥12 increased with time from 55% to 68%, and there was
a decline in patients with <4 NPI total score from 37% to 25% (Figure 3).
Nearly all (97%) patients had a NPI total score ≥16 ever, and half of the
patients (49%) had a NPI total score ≥36 ever during the study period.
3.1.2 | NPI items
The percentage of patients with item score ≥4 at each assessment is
presented in Figure 4 (numerical in DS 2). Apathy was the most com-
mon item (83%) at each assessment with high stable annual frequency
(37%‐48%), while 9 of the 12 items had stable crude frequency around
25% (Figure 4, DS 2). Cognitive decline was associated with a higher
probability of delusions, hallucinations, agitation, apathy, and aberrant
motor behavior, all with small effect sizes (ORs of 1.5‐2, P = .009‐
<.001, DS 1). Females were more at risk for delusions (OR 2.4,
P = .008) and anxiety (OR 2.3, P = .006), but less at risk for apathy
(OR 0.46, P = .002). Time in itself, when adjusted for cognitive decline,
showed no significant effect on items, with the exception euphoria/
elation which was infrequent (Figure 4, DS 2).
Apathy was also the symptom most often ever reported (83%) in
follow‐up; other common items were depression (63%), appetite
(63%), and aberrant motor behavior (60%, Table 3). The item profile
was similar in using ≥1 and ≥4 as the cut‐off. Persistency of a symp-
tom (present at next follow‐up) ranged from 53% to 74%, but declined
when cut‐off was raised to ≥4 (35%‐59%). Reoccurrence of a symp-
tom (present at any 2 follow‐ups) increased from 34% to 84% to
57% to 86% when cut‐off was raised from ≥1 to ≥4, respectively.
TABLE 1 Baseline characteristics
Alzheimer's disease (n = 106) Lewy body dementia (n = 97)
t/z P
Age (mean, SD)a 75.3 7.8 75.3 7.8 75.2 7.2 0.05 .957
Female percentageb 71% 46% 45% −3.97 <.001
Years of education (mean, SD)a 9.6 2.9 9.8 2.9 9.7 2.8 −0.22 .826
Years of symptoms (mean, SD)a 2.2 2.2 1.9 1.8 2.7 2.1 −2.73 .007
MMSE score (mean, SD)a 23.7 2.4 23.7 2.2 23.7 3.1 −0.28 .774
AD; Alzheimer's disease; LBD; Lewy body dementia; MMSE; Mini Mental State Examination; SD; standard deviation.
aStudent's t‐test showing t‐score for AD and LBD.
bMann‐Whitney U test, showing z‐score for AD and LBD.
FIGURE 2 Course of Neuropsychiatric
Inventory total scores in mild dementia
cohort, Alzheimer's disease, and Lewy body
dementia for 5 years. NPI, Neuropsychiatric
inventory; MDC, Mild dementia cohort (black);
AD, Alzheimer's disease (blue); LBD, Lewy‐
body dementia (green); n, number of patient
at assessments. Error bars show 95%
confidence interval [Colour figure can be
viewed at wileyonlinelibrary.com]
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3.2 | Comparison between AD and LBD
3.2.1 | Total NPI score
Lewy body dementia patients had a higher NPI‐total score (OR 2.58,
P < .001) over 5 years; this association was reduced when adjusted
for cognitive decline (OR 1.79, P = .015), which is steeper in LBD
patients in this cohort23 (Table 2). The difference between LBD and
AD was most pronounced during the first years, but there were only
23 LBD patients alive in the study at year 5 (Figure 2).
3.2.2 | NPI item frequency
The frequency of NPI item scores ≥4 for LBD and AD is presented in
Figure 2 and Table DS5. Lewy body dementia had stable and signifi-
cant higher frequency of hallucinations with a large effect size (OR
6.8, P < .001, DS 1). The association between LBD and increased
frequency of delusions and apathy was similar, with moderate effect
sizes (OR 2.9, P < .001 and 2.6, P = .006), although the association
between LBD and apathy decreased with time (OR 0.65, P < .001)
with concurrent increase in AD. The likelihood of ever experiencing
apathy was similar between AD and LBD, while the likelihood of hal-
lucinations (AD 24%, LBD 66%) and delusions (AD 41%, LBD 53%)
were higher in LBD than AD (Table 3).
4 | DISCUSSION
4.1 | Summation of findings
This is one of the first studies following a cohort of both AD and
LBD from the diagnosis of mild dementia and 5 years onward with
FIGURE 3 Frequency of different
Neuropsychiatric Inventory total scores in
mild dementia cohort
TABLE 2 Neuropsychiatric symptom total score, Lewy body dementia, and cognitive declinea
Model 1 Model 2
LBD and Covariatesa LBD, Covariates, and MMSE Declineb
Fixed eff. OR SE P LLCI ULCI OR SE P LLCI ULCI
Age 1.04 0.02 .238 1.01 1.07 1.01 0.02 .352 0.98 1.04
Female 0.93 0.23 .750 0.57 1.49 0.93 0.22 .754 0.58 1.48
Time 1.70 0.09 <.001 1.53 1.89 1.01 0.06 .908 0.89 1.14
LBD 2.58 0.62 <.001 1.61 4.11 1.79 0.43 .015 1.12 2.86
MMSEc 1.47 0.14 <.001 1.22 1.77
Proportional odds model with random slope and intercept. NPI‐total collapsed into 4 categories (0 = no symptoms, 0‐16 = mild, 17‐30 = moderate,
>30 = severe, based on frequencies, even membership). Random effects not shown.
OR, odds ratio; SE, standard error; P, P value; LLCI, lower level confidence interval; ULCI, upper level confidence interval; eff, effects; LBD, Lewy body
dementia; MMSE, Mini Mental State Examination.
aNPI total as ordinal with age, gender, time (linear), and LBD.
bSame model as above, but with MMSE decline as a time‐varying covariate.
cTransformation with √(30 − MMSE).
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annual assessments of NPS and low attrition rate. There was only
a moderate increase in NPI total score from 15 to 17 during the
study period and no increase in the proportion with high NPI total
scores. Neuropsychiatric symptoms are present in all patients with
dementia and severe NPS occurred in nearly half of them. Cogni-
tive decline was associated higher NPI total score and several
NPI items, but only the frequency of apathy increased significantly
with time, and only for AD. Patients with LBD had higher NPI
FIGURE 4 Frequency Neuropsychiatric Inventory items ≥4 for 5‐year follow‐up. NPI, Neuropsychiatric inventory; MDC, Mild dementia cohort
(n = 188, black); AD, Alzheimer's disease (n = 116, blue); LBD, Lewy‐body dementia (n = 87, green). Note: MDC includes 116 AD, 52 LBD and 20
other dementia patients a‐edenotes p‐value < 0.05 for probability of symptoms in multivariate analysis in aDLB, bfemale, ccognitive decline, dtime,
eLBD with time [Colour figure can be viewed at wileyonlinelibrary.com]
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total score and more hallucinations than AD patients throughout
the study.
4.2 | Strengths and limitations
Our data may have potential recruitment bias because of referrals of pri-
mary care patients, which may have led to an increased number of
patients with complicated dementia or NPS. However, GPs were invited
to refer any patients with suspected dementia, and patients were
included from psychiatric, neurologic, and geriatric clinics. Mild dementia
was defined as CDR = 1 or MMSE of 20 or more. Mini Mental Status
Examination is language and memory dominant and thus less sensitive
to the earliest changes in the LBD patients, which included both PDD
and DLB, although the sensitivity of MMSE is comparable to other
screening instruments when approaching moderate dementia levels.24
Because of the naturalistic design, patientswere treated according to rec-
ommendations for pharmacological and nonpharmacological treatment
which likely influence the course of NPS, but because treatment was
not standardized in the study, individual treatment differences may have
influenced the course of NPS. We used the NPI to assess NPS, which
does not capture the full spectrum of NPS and is entirely based on carer
report and thus not subjective experience of the patients. Finally, because
of high mortality, only half of the patients completed the 5‐year follow‐
up. There was an expected high mortality, particularly in LBD,25 which
may have confounded the observed course of NPS.
Strengths of the study include the long follow‐up time, annual
assessments with structured instruments, and the very high complete-
ness of data except attrition because of death, which allowed for per-
sistency and reoccurrence analysis from mild to severe dementia. This
is also 1 of the largest long‐term studies of NPS in LBD. The diagnostic
procedures were rigorous, and high accuracy was demonstrated in the
56 cases with neuropathological diagnosis.16
4.3 | High NPS scores are common also in early
dementia
Neuropsychiatric symptoms are generally assumed to increase with
severity,26 and the observed stable frequency of high NPI total scores
early in disease is therefore important. Neuropsychiatric symptoms
are strongly associated with key outcome variables such as caregiver
distress, quality of life,27 and hospitalization.28 A quarter of the
patients at any time had NPI total score >36, which is above the score
considered in need of antipsychotic drug treatment in trials.20,21 Previ-
ous longitudinal studies have reported that NPS increase over time,5,29
and are associated with duration of disease22 and time.30 Our finding
that NPS are associated with cognitive decline is also consistent with
other studies.30-32 However, this increase is small, and likely of minor
clinical relevance. Recently, Brodaty et al4 showed an increase in NPS
with dementia progression, but in a cohort with only 1.9% LBD, and
where atypical antipsychotics were used by 21%, suggesting differ-
ence compared our study in both selection and treatment.
The high follow‐up rate and attempts to include all patients with
newly diagnosed dementia in the defined geographical area lend support
to our findings that NPS is prevalent already early in dementia. The het-
erogeneity of the studies of NPS makes meta‐analysis difficult and intro-
duces referral bias also in reviews.5 All patients in this study received
standard treatment to the best of current practice, including reassessment
and interventions if needed, and participants with severe NPS have likely
received pharmacological and nonpharmacological intervention which
could affect NPS. The presence of severe NPS early in dementia is thus
an important finding with clinical and health economic consequences.
4.4 | NPS are highly frequent throughout dementia
Our observations that NPS are very common in dementia through the
5‐year course after diagnosis extend previous reports. Half of
TABLE 3 Full Neuropsychiatric Inventory item descriptive from all years
Mild Dementia Cohort (n = 188) AD LBD AD LBD AD LBD
Ever Persistency Reoccurrence Median Ever >1 Ever >4 Median
NPI item >1 >4 >1 >4 >1 >4
Delusions 64% 44% 53% 50% 59% 72% 4 59% 75% 41% 53% 4 6
Hallucinations 52% 35% 69% 57% 63% 71% 4 40% 89% 24% 66% 4 4
Agitation/aggression 68% 44% 53% 56% 66% 78% 4 68% 60% 40% 43% 3 4
Dysphoria/depression 89% 63% 64% 59% 83% 86% 3 88% 94% 66% 61% 3 3
Anxiety 75% 49% 51% 40% 65% 78% 3 74% 74% 51% 41% 3 3
Euphoria 22% 11% 59% 28% 34% 57% 3 25% 14% 14% 7% 4 3
Apathy 91% 83% 64% 43% 82% 85% 6 91% 93% 82% 84% 6 6
Disinhibition 61% 37% 55% 50% 66% 80% 3 59% 55% 36% 23% 3 2
Irritability 76% 53% 55% 45% 71% 86% 4 76% 72% 50% 46% 4 4
Aberrant motor behavior 67% 60% 74% 35% 59% 66% 6 69% 66% 60% 59% 6 6
Sleep 65% 53% 48% 40% 61% 70% 6 58% 80% 47% 66% 6 6
Appetite 71% 63% 42% 31% 59% 62% 6 70% 67% 62% 57% 6 6
Ever is frequency of patients to have 1 or more item score (≥1 or ≥4) throughout study. Persistency is the frequency item score (≥1 or ≥4) present next
follow‐up (12 months). Reoccurrence is the frequency of patients having the same symptom at several assessments if present once. Median is calculated
from those with positive screening question at assessments.
NPI, Neuropsychiatric Inventory; MDC, mild dementia cohort (n = 188); AD; Alzheimer's disease (n = 116); LBD, Lewy body dementia (n = 87).
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dementia patient experienced severe NPS (NPI total ≥ 36). Our
reported ever scores are consistently higher than 5‐year prevalence
score reported in the Cache County study,3 and with higher complete-
ness of data. There were few deaths during the first years of the
study, allowing for quite complete dataset of early dementia. Apathy
is the most frequent item overall, which is different from other studies
showing depression as most frequent.3,5,31,33 The clinical distinction
between apathy and depression, especially in more severe dementia
is challenging,34 and our ≥4 cut‐off may also favor a consistent symp-
tom as apathy in the NPI item score.
Stable factors such as diagnosis and gender were more important
risk factors for NPI than further cognitive decline after the diagnosis
of dementia and study inclusion, indicating that NPS do not solely
arise secondary to cognitive decline.
4.5 | Symptoms fluctuate and relapse
The frequency of each item is in line with a comparable longitudinal
study,4 showing stable frequency of many NPI items. The persistency
of items reported in our study is higher than reported in most studies,5
but consistent with studies of longer duration.35 Patients had ongoing
follow‐up all year at demand as hospital outpatients, while the 12‐
month persistency reflect assessments assumed to be in clinical stable
condition with minimal referral bias and representative of current clin-
ical practice.26 To describe the dynamics of NPS, we report a reoccur-
rence rate, and with the narrow time span of NPI (4 weeks out of 52),
the actual relapse of symptoms is probably higher. The persistency
and reoccurrence still demonstrate fluctuant symptoms, suggesting
that NPI items represent states rather than traits. The lower risk of
not being present at next assessment (lower persistency) and the
higher risk of symptom relapse (reoccurrence) for item scores ≥4 rather
than ≥1 suggest better precision when assessing need for clinical
intervention when using the ≥4 cut‐off.
4.6 | Difference between AD and LBD
Diagnosis has considerable effect on NPS frequency. Few longitudinal
comparative studies exist, and our findings show that these differ-
ences tend to decrease with increasing severity of disease. For exam-
ple, apathy tended to increase in AD but not LBD. This may explain
why other studies have not reported NPS differences between AD
and LBD.29 On the other hand, hallucinations had consistently higher
frequency in LBD than AD, in line with data from previous longitudinal
studies with shorter duration.36 Hallucinations are associated with
more severe cognitive decline and early institutionalization, and thus
is a key NPS. Unfortunately, there is no systematic evidence regarding
how to treat hallucinations in dementia with Lewy bodies,26 although
pimavanserin, a 5HT2a inverse agonist, has demonstrated positive
effects on psychosis in Parkinson's disease and may represent a
potential candidate also in LBD.37 A large Taiwanese study reported
more frequent and more severe depression in dementia with Lewy
bodies compared to AD using DSM‐4 diagnosis, with largest differ-
ence in symptoms such as anhedonia and fatigue.38 We report more
depressive symptom with higher MADRS score at baseline, higher
apathy in LBD early in course, and overall more sleep disturbances in
LBD, but NPI item depression did not show any difference between
groups. Difference in severity of early NPS and profile of depressive
symptoms may indicate need for different diagnostic and treatment
strategies for NPS in AD and LBD.
4.7 | Implications
The high frequency of severe NPS throughout the 5‐year period high-
lights the need for health service planning to address NPS from time
of dementia diagnosis. Disease‐related differences in NPS profile and
course underline the importance of careful diagnosis in studies. The
high reoccurrence rate suggests that clinical intervention at first time
occurrence of symptoms may be appropriate and the fluctuations of
symptoms suggest vigilance in effect evaluation and clinical trial
design. Neuropsychiatric symptoms are an integrated part of dementia
and need tailored and dynamic nonpharmacological management26
throughout disease course. Clinical trials on NPS in dementia with
Lewy bodies are a priority. Informing health care providers and raising
public awareness on the early occurrence of NPS and its management
are crucial.
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DS1. Neuropsychiatric symptom items: Alzheimer’s disease versus Lewy-body dementiaa 
 Delusionsb Hallucinationsb Agitationc Depressionb Anxietyc Euphoriad 
             
 OR p OR P OR P OR p OR p OR P 
Age 1.04 0.097 1.01 0.644 1.06 0.010 0.98 0.106 0.97 0.126 1.28 0.030 
Female 2.44 0.008 0.99 0.980 0.65 0.203 1.33 0.189 2.28 0.006 1.48 0.035 
Time 0.87 0.114 1.05 0.524 1.10 0.276 0.95 0.398 1.03 0.761 1.29 <0.001 
MMSE 1.70 <0.001 1.47 <0.001 1.41 0.019 1.19 0.089 1.14 0.321 1.17 0.080 
LBD 2.88 0.001 6.86 <0.001 1.08 0.837 1.17 0.467 1.08 0.799 1.80 0.001 
             
 Apathyc Disinhibitionc Irritabilityc Motorc Sleepc Appetitec 
             
 OR p OR P OR P OR p OR p OR P 
Age 1.01 0.568 1.05 0.075 1.03 0.174 0.99 0.369 1.03 0.231 1.01 0.933 
Female 0.46 0.002 0.85 0.698 0.92 0.823 1.83 0.032 0.63 0.171 1.26 0.321 
Time 1.19 0.024 1.37 0.051 1.05 0.680 1.08 0.416 0.92 0.459 0.89 0.141 
MMSE 1.31 0.009 1.30 0.146 1.24 0.148 1.75 <0.001 1.12 0.411 1.13 0.268 
LBD 2.64 0.006 0.70 0.401 0.84 0.623 1.53 0.119 2.25 0.012 1.04 0.862 
LBD*T 0.65 <0.001           
Abbreviations: OR; odds ratio, p; p-value, MMSE; transformed to √(30 – MMSE), LBD; Lewy-body dementia T; 
Time. 
a Mixed effects logistic regression, NPI items ≥ 4. 
b Random intercept model 
c Random intercept, random slopes model 


































































































































































































































































































































































































































































































































































































































































































Methodological supplements article 3 
Sampling and characterisation of post-mortem brain samples  
Brain dissection, macroscopic description, regional sampling, tissue processing and 
staining were done following standard protocols including BrainNet Europe and 
Brains for Dementia Research UK [1-6]. Block taking for histological and 
immunohistochemical studies and neuropathological assessment of 
neurodegenerative and control cases was performed in accordance with published 
guidelines [1-4, 7-9]. For histology, 7μm thick sections were cut and stained with 
hematoxylin and eosin (H&E) and selected blocks also with Luxol fast blue/Nissl 
(LFB/Nissl) for first stage neuropathological assessment of cytoarchitecture and basic 
cytopathology (for example the presence of Lewy bodies), extent and 
neuroanatomical distribution of neuronal and myelin loss, and selection of tissue 
blocks for detailed immunohistochemical analysis. 
Immunohistochemistry  
Briefly, 7 μm-thick paraffin sections were routinely de-waxed, blocked for endogenic 
peroxidase activities in ethanol containing 1.5% (v/v) H2O2, and heat-treated in 
appropriate antigen retrieval buffer solutions using a household electronic pressure 
cooker. After protein blocking in 50 mM TRIS-buffered saline (TBS pH 7.4) 
containing 5% (w/v) low fat milk powder, the sections were incubated with the 
primary antibodies at room temperature for 70 min. Detection was performed using 
Novolink polymer kit (Leica Biosystems/Novocastra), and nuclear staining was 
carried out with Mayer’s hematoxylin. For primary goat antibody, rabbit anti-goat 
linker IgG (GenWay Biotech), for primary rat antibody, rabbit anti-rat linker IgG 
(Vector Laboratories) were used.  
Immunostaining (location and intensity) was examined by a consultant 
neuropathologist and the intensity and frequency of respective nuclear and of 
3 
 
cytoplasmic staining assessed scored using the following standard semiquantitative 
scale: 0 - no staining, 1 - mild staining, 2 - moderate staining and 3 - intense staining. 
Antibodies  
Primary antibodies dilutions used in this study are as follows: mouse monoclonal 
anti-amyloid-β (Agilent/DAKO)(1:100), rat monoclonal anti-phospho-TDP-43 (Ser 
409/410)(Merck/Millipore)(1:100), rabbit polyoclonal anti-phospho TDP-43 
(pSer409/410-1)(Cosmo-Bio)(1:1000), mouse monoclonal anti-phospho-tau (Ser 
202/Thr205) (ThermoFisher/Invitrogen) (1:100), goat polyclonal anti-α-synuclein 
(R&D Systems)(1:1.000), mouse monoclonal anti α-synuclein (clone 
5G4)(Roboscreen)(1:2.000), mouse monoclonal anti-p62 (lck ligand)(1:200)(BD 
Biosciences), rabbit polyclonal anti-ubiquitin (DAKO)(1:1.000). Fixation time varied 
considerably in our cohort which may have affected immunoreactivity, especially 
regarding α-synuclein. Therefore, we applied two α-synuclein antibodies when 
immunoreactivity was unequivocal or inconsistent with findings on, HE and p62 
(which was applied when primary immunohistochemical work-up was negative or 
immunoreactivity questionable).  
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